BAD2016
Meeting App....

• Review agenda & speakers
• Interactive floorplans
• View abstracts & e-posters
• View sponsors & exhibitors

Follow these steps to download the app to your smart device:

Download the Guidebook app from the iOS App Store or Google Play
Tap on “Use Code” below the Guidebook logo
Enter the passphrase: bad2016
Tap “Get this Guide” on the next screen that appears

Using a Blackberry, Windows Phone, or computer?
You can access the guide through a web browser at https://guidebook.com/g/bad96/
– enter the passphrase bad2016 when prompted.

...download now

BAD are grateful to Janssen for their support of the meeting app
### Overview

- **Accommodation**: 9
- **App**: 1
- **Badges**: 9
- **Banking**: 9
- **Business Services**: 9
- **Catering**: 9
- **Certificates of Attendance**: 9
- **Cloakroom**: 9
- **Committee Meetings**: 12
- **Continuing Professional Development (CPD)**: 9
- **Exhibition**: 9
- **Exhibition Quiz**: 9
- **Exhibition Plan**: 74-75
- **First Aid**: 9
- **Focus Sessions**: 66
- **Hand Eczema Assessment Tool Training Session**: 68
- **Hot Topics Overview**: 67
- **Map of Birmingham**: 82-83
- **Meetings Calendar**: 81
- **Organising Committees**: 4
- **Parking**: 9
- **Patient Support Groups**: 75
- **Payment of Registration Fees**: 9
- **Pharma Presentation Zone**: 67
- **Poster Exhibition**: 9
- **Poster Presentations**: 69
- **Posters**: 70-73
- **Programme Overview**: 6
- **Registration Desk**: 9
- **Social Events**: 11
- **Speaker Preview**: 9
- **Sponsored Symposia**: 9
- **Venue Plan**: 10
- **Welcome to Birmingham**: 5
- **Well being area**: 9

### Monday 4th July Overview

- **BSD Self-Assessment**: 14
- **Trainee Pre-Conference Session**: 15
- **SAS Session**: 16

### Tuesday 5th July Overview

- **British Society of Cutaneous Allergy (BSCA)**: 18-19
- **CPCs – Joint BAD / BSD**: 20
- **British Society for Dermatological Surgery (BSDS)**: 21-23
- **British Society for Skin Care in Immunosuppressed Individuals**: 24-25
- **British Society for Dermatopathology (BSD)**: 26-27
- **THESIS working lunch**: 28
- **BSACI Guest Society Session**: 29
- **Senior Skin Group**: 30
- **Dermatology Teachers**: 31
- **Plenary Session**: 32

### Wednesday 6th July Overview

- **Sponsored Symposium: LEO Pharma**: 34
- **Sponsored Symposium: Celgene**: 35
- **Plenary Session – Medical Dermatology**: 36
- **British Cosmetic Dermatology Group (BCDG)**: 37
- **International Psoriasis Council – Meet the Expert**: 38
- **Improving Patient Wellbeing and Outcomes**: 39
- **Sponsored Symposium: La Roche-Posay**: 40
- **Sponsored Symposium: Lilly**: 41
- **Sponsored Symposium: Sanofi Genzyme**: 42
- **Submitted Papers**: 43
- **British Society for Investigative Dermatology (BSID)**: 44
- **Psychodermatology UK**: 45-46
- **Historical Symposium**: 47-48
- **British Teledermatology Society (BTS)**: 49
- **Plenary Session**: 50
- **Sponsored Symposium: Sobi**: 51
- **Sponsored Symposium: Bristol Myers Squibb**: 52

### Thursday 7th July Overview

- **Plenary Session – International Dermatology**: 54
- **British Society of Paediatric Dermatology (BSPD)**: 55-56
- **British Photodermatology Group (BPG)**: 57-58
- **UK Trend**: 59
- **Registrars Symposium**: 60
- **British Hair & Nail Society (BHNS)**: 61
- **BADGEM**: 62-63
- **Plenary Session**: 64-65
- **CPD Update**: 66

### KEYNOTE LECTURES

#### Tuesday 5th July

- **Professor Martin Cook**: 32
- **Professor Michael Veness**: 32

#### Wednesday 6th July

- **Professor Kieron Leslie**: 50
- **Professor Donald Leung**: 50

#### Thursday 7th July

- **Dr Chetan Mukhtyar**: 64
- **Professor Irwin McLean**: 65
CONFERENCE & EVENT SERVICES
Mr Chris Garrett – Conference & Event Services Manager
Mrs Jenna Bowler – Senior Events Coordinator
Mrs Marie Elwér – Finance and Conference Administrator
Miss Sally-Ann Koomson – Marketing & Events Coordinator
Miss Danniele Sinclair – Events Coordinator

ORGANISING COMMITTEE
Miss Marilyn Benham Mrs Jenna Bowler
Dr David Eedy Mr Chris Garrett
Dr Mark Griffiths Dr Richard Groves
Mrs Catherine Hanaway Dr Nick Levell – Chair
Dr Vincent Li Dr Ruth Murphy
Dr Jui Vyas Dr Richard Weller

BAD ABSTRACT SELECTION COMMITTEE
Dr Asok Biswas Dr Sara Brown
Dr Paul Craig Dr Emma Craythorne
Dr Sara Edward Dr Mark Griffiths
Dr Nick Levell Dr Blanca Martin
Dr Sandy McBride Dr Ruth Murphy
Dr Richard Weller

BAD JUDGING COMMITTEE
Dr Sadiq Alkali Dr Michael Ardern-Jones
Dr Alison Bedlow Prof Chris Bunker
Dr Andrew Carmichael Prof Rino Cerio
Dr Fiona Child Dr Ian Coulson
Dr Carsten Flohr Dr Karen Gibbon
Dr Mark Griffiths Dr Shikha Gupta
Dr Jenny Hughes Dr Sally Ibotson
Dr Brian Kirby Dr Elise Kleyn
Dr Sinead Langan Dr Vincent Li
Dr Tom Lucke Dr Sandy McBride - Chair
Dr Tess McPherson Dr Simon Meggitt
Dr Bav Shergill Dr Victoria Swale
Dr Anne-Marie Tobin Dr Maureen Walsh

BADGEM ABSTRACT SELECTION COMMITTEE
Prof Irene Leigh
Prof Edel O’Toole
Dr Neil Rajan

BCDG ABSTRACT SELECTION COMMITTEE
Dr Sean Lanigan
Dr Bav Shergill
Dr Nisith Sheth

BHNS ABSTRACT SELECTION COMMITTEE
Dr Matthew Harries
Dr Paul Farrant
Dr Susan Holmes

BPG ABSTRACT SELECTION COMMITTEE
Dr Robert Dawe Dr Giles Dunnill
Dr Adam Fityan Prof James Ferguson
Dr Victoria Goulden Dr Tsui Ling
Dr Paul Norris Dr Ljubomir Novakovic
Dr James Powell Dr Robert Sarkany
Dr Muthu Sivaramakrishnan Dr Sophie Weatherhead

BSCA ABSTRACT SELECTION COMMITTEE
Dr Deidre Buckley
Dr Christine Reckling
Dr Natalie Stone

BSPD ABSTRACT SELECTION COMMITTEE
Dr Paula Beattle
Dr Fiona Browne
Dr Jemima Mellerio
Dr Lea Solman Kosutic

BSD ABSTRACT SELECTION COMMITTEE
Dr Asok Biswas
Dr Paul Craig
Dr Sara Edward
Dr Blanca Martin

BSDS ABSTRACT SELECTION COMMITTEE
Dr Vindy Ghura
Dr Wal Hussain
Dr Stephen Keohane

BSSCII ABSTRACT SELECTION COMMITTEE
Prof Christopher Bunker
Prof Catherine Harwood
Dr Ferina Ismail
Dr John Lear
Dr David Paige
Dr Conal Perrett
Prof Charlotte Proby
Dr Helen Ramsay

BTS ABSTRACT SELECTION COMMITTEE
Dr Veronique Bataille
Dr Pawel Bogucki
Dr Saul Halpern
Dr Andy MacFarlane
Dr Colin Morton

DERMATOLOGY TEACHERS SELECTION COMMITTEE
Dr Stuart Cohen
Dr Alison Honan
Dr Shona Ogilvie
Dr Minal Singh
Dr Angela Tewari

HISTORICAL ABSTRACT SELECTION
Dr Julia Ellis
Dr David Gawkrodger
Dr Frances Humphreys
Dr Nick Levell
Dr Sid Orpin
Dr Paul Yesudian

HISTORICAL ABSTRACT SELECTION
Dr Janet Angus
Dr Susannah Baron
Dr Anthony Bewley

ACKNOWLEDGEMENTS
The British Association of Dermatologists gratefully acknowledges the contribution of the many exhibitors & sponsors whose attendance has helped make the meeting possible.
Welcome to Birmingham and the 96th Annual Meeting of the British Association of Dermatologists. We are once again delighted to be in the award winning Birmingham International Convention Centre.

Birmingham is a modern city that lies right at the centre of the UK’s motorway network enabling easy access to the rest of the UK. It has the UK’s largest interchange main rail station and it also has one of the most accessible international airports in Europe. So getting here is simple! Once here, Birmingham is a city of culture and heritage with food, art and a dynamic vibrant atmosphere.

SCIENTIFIC PROGRAMME

Building on the BAD annual meeting’s reputation as a high quality internationally renowned event, the BAD Conference and Events committee has again worked hard to provide a blend of new scientific presentations with updates from experts in various fields. We are pleased that the Arthur Rook Oration will be delivered by Professor Irwin McLean from Dundee. Professor Martin Cook (Guildford) and Professor Michael Veness (Sydney, Australia), will give the first of the keynote lectures at the plenary session on Tuesday speaking on ‘The interpretation of sentinel lymph nodes for melanoma’ and ‘Radiotherapy and skin cancer: The never ending battle and the perspective of an Aussie Radiation Oncologist’ respectively. Wednesday afternoons programme features Professor Kieron Leslie from San Francisco who will update the membership on ‘Hot Ice, methinks: all you need to know about autoinflammation as explained by William Shakespeare’. Also on Wednesday afternoon we have a keynote lecture to be given by Professor Donald Leung from Denver, USA speaking on ‘Mechanisms of Infection in Atopic Dermatitis’. The final keynote lecture will come from Dr Chetan Mukhtyar (Norwich), talking during the plenary session on Thursday afternoon on ‘Recent advances in vasculitis’.

We are welcoming the British Society for Allergy and Clinical Immunology as guests to our meeting. Dr Helen Brough and Dr Carsten Flohr have put together an exciting programme on Tuesday afternoon.

We have a new Improving Patient Wellbeing and Outcomes session on Wednesday morning that has been organised by the patient support groups. Please also look out for the Hot topics and Poster Presentations within the Exhibition Hall and Hall 4. Don’t forget to download the new BAD2016 app and see the new features as we look to improve our audience interaction (details on page 1).

On Monday 4th July we will be holding pre-conference sessions for trainees, Specialty & Associate Specialist doctors, medical students and there will be a BSD self assessment session.

This year we introduce BAdfest on Tuesday evening. Bringing the spirit of a festival to the conference, expect dazzling entertainment, street food and drinks. We hope this will be a perfect opportunity to relax, catch up with old acquaintances and form new friendships. This event will be taking place in Hall 4 and surrounding areas of ICC Birmingham. All attendees are invited to attend.

It all promises to be a packed and memorable conference, I look forward to offering a warm welcome to all delegates and hope you enjoy the meeting!

Dr Nick Levell
Clinical Vice President (President –elect) 2014-2016
## Programme Overview

### MONDAY 4 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION DETAIL</th>
<th>ROOM</th>
<th>INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 – 18:15</td>
<td>BSD Self-Assessment</td>
<td>Executive 2</td>
<td>Page 14</td>
</tr>
<tr>
<td>12:15 – 18:00</td>
<td>Trainee Pre-conference Session</td>
<td>Hall 5</td>
<td>Page 15</td>
</tr>
<tr>
<td>12:15 – 17:35</td>
<td>Staff &amp; Associate Specialist Session</td>
<td>Hall 8a</td>
<td>Page 16</td>
</tr>
</tbody>
</table>

### TUESDAY 5 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION DETAIL</th>
<th>ROOM</th>
<th>INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 12:00</td>
<td>British Society of Cutaneous Allergy</td>
<td>Hall 9</td>
<td>Page 18-19</td>
</tr>
<tr>
<td>08:45 – 10:23</td>
<td>Clinicopathological Cases</td>
<td>Hall 1</td>
<td>Page 20</td>
</tr>
<tr>
<td>08:45 – 16:15</td>
<td>British Society for Dermatological Surgery</td>
<td>Hall 5</td>
<td>Page 21-23</td>
</tr>
<tr>
<td>09:00 – 12:30</td>
<td>British Society for Skin Care in Immunocompromised Individuals</td>
<td>Hall 10b</td>
<td>Page 24-25</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>10:40 – 10:55</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>11:00 – 16:15</td>
<td>British Society for Dermatopathology</td>
<td>Hall 1</td>
<td>Page 26-27</td>
</tr>
<tr>
<td>12:15 – 13:00</td>
<td>Pharma Presentations</td>
<td>Exhibition Hall</td>
<td>Page 67</td>
</tr>
<tr>
<td>12:15 – 14:30</td>
<td>THESIS working lunch - open to all</td>
<td>Executive 7</td>
<td>Page 28</td>
</tr>
<tr>
<td>13:00 – 14:35</td>
<td>BSACI Guest Society Session</td>
<td>Hall 9</td>
<td>Page 29</td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td>Senior Skin Group</td>
<td>Hall 10b</td>
<td>Page 30</td>
</tr>
<tr>
<td>13:15 – 14:15</td>
<td>Dermatology Teachers</td>
<td>Hall 10a</td>
<td>Page 31</td>
</tr>
<tr>
<td>14:30 – 15:00</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>14:40 – 14:55</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Keynote Lecture: Professor Martin Cook</td>
<td>Hall 1</td>
<td>Page 32</td>
</tr>
<tr>
<td>15:30 – 16:30</td>
<td>Plenary Session</td>
<td>Hall 1</td>
<td>Page 32</td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td>Keynote Lecture: Professor Michael Veness</td>
<td>Hall 1</td>
<td>Page 32</td>
</tr>
<tr>
<td>17:15 – 18:45</td>
<td>AGM – BAD members only</td>
<td>Hall 1</td>
<td>Page 11</td>
</tr>
<tr>
<td>17:30 – 22:00</td>
<td>BADfest</td>
<td>Hall 4</td>
<td>Page 11</td>
</tr>
</tbody>
</table>

### WEDNESDAY 6 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION DETAIL</th>
<th>ROOM</th>
<th>INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 – 08:30</td>
<td>Christian Medical Fellowship Breakfast</td>
<td>Executive 2</td>
<td>Page 34</td>
</tr>
<tr>
<td>07:45 – 08:30</td>
<td>LEO Pharma Sponsored Symposium</td>
<td>Hall 10</td>
<td>Page 35</td>
</tr>
<tr>
<td>07:45 – 08:30</td>
<td>Celgene Sponsored Symposium</td>
<td>Hall 9</td>
<td>Page 35</td>
</tr>
<tr>
<td>08:30 – 12:25</td>
<td>Plenary session - Medical Dermatology</td>
<td>Hall 1</td>
<td>Page 36</td>
</tr>
<tr>
<td>08:45 – 12:45</td>
<td>British Cosmetic Dermatology Group</td>
<td>Hall 8a</td>
<td>Page 37</td>
</tr>
<tr>
<td>10:30 – 10:50</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>10:30 – 10:50</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td>International Psoriasis Council – Meet the expert</td>
<td>Hall 5</td>
<td>Page 38</td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td>Improving Patient Wellbeing and Outcomes</td>
<td>Hall 9</td>
<td>Page 39</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>La Roche-Posay Sponsored Symposium</td>
<td>Hall 9</td>
<td>Page 40</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Lilly Sponsored Symposium</td>
<td>Hall 10</td>
<td>Page 41</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Sanofi Genzyme Sponsored Symposium</td>
<td>Hall 5</td>
<td>Page 42</td>
</tr>
<tr>
<td>14:00 – 15:15</td>
<td>Scientific Session – submitted papers</td>
<td>Hall 1</td>
<td>Page 43</td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>British Society for Investigative Dermatology - open to all</td>
<td>Hall 8a</td>
<td>Page 44</td>
</tr>
<tr>
<td>14:30 – 17:25</td>
<td>Psychodermatology</td>
<td>Hall 5</td>
<td>Page 45-46</td>
</tr>
<tr>
<td>14:30 – 15:45</td>
<td>Historical Symposium</td>
<td>Hall 9</td>
<td>Page 47-48</td>
</tr>
<tr>
<td>14:30 – 17:00</td>
<td>British Teledermatology Society</td>
<td>Hall 10</td>
<td>Page 49</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>15:30 – 16:30</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>16:00 – 16:15</td>
<td>Presidents Address – Dr Nick Levell</td>
<td>Hall 1</td>
<td>Page 50</td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td>Keynote Lecture: Professor Kieron Leslie</td>
<td>Hall 1</td>
<td>Page 50</td>
</tr>
<tr>
<td>16:45 – 17:45</td>
<td>Plenary Session</td>
<td>Hall 1</td>
<td>Page 50</td>
</tr>
<tr>
<td>17:45 – 18:15</td>
<td>Keynote Lecture: Professor Donald Leung</td>
<td>Hall 1</td>
<td>Page 50</td>
</tr>
<tr>
<td>18:15 – 19:00</td>
<td>Sobi Sponsored Symposium</td>
<td>Hall 9</td>
<td>Page 51</td>
</tr>
<tr>
<td>18:15 – 19:00</td>
<td>Bristol Myers Squibb Sponsored Symposium</td>
<td>Hall 10</td>
<td>Page 52</td>
</tr>
</tbody>
</table>

### THURSDAY 7 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION DETAIL</th>
<th>ROOM</th>
<th>INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 10:05</td>
<td>Plenary session – International Dermatology</td>
<td>Hall 1</td>
<td>Page 54</td>
</tr>
<tr>
<td>08:30 – 12:02</td>
<td>British Society for Paediatric Dermatology</td>
<td>Hall 5</td>
<td>Page 55-56</td>
</tr>
<tr>
<td>08:30 – 12:15</td>
<td>British Photodermatology Group</td>
<td>Hall 9</td>
<td>Page 57-58</td>
</tr>
<tr>
<td>08:30 – 10:00</td>
<td>UK Trend</td>
<td>Hall 10</td>
<td>Page 59</td>
</tr>
<tr>
<td>10:15 – 10:45</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>10:15 – 10:35</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>10:45 – 12:15</td>
<td>Registrars Symposium</td>
<td>Hall 1</td>
<td>Page 60</td>
</tr>
<tr>
<td>10:45 – 12:15</td>
<td>British Hair &amp; Nail Society</td>
<td>Hall 10</td>
<td>Page 61</td>
</tr>
<tr>
<td>12:30 – 13:15</td>
<td>Pharma Presentations</td>
<td>Exhibition Hall</td>
<td>Page 67</td>
</tr>
<tr>
<td>13:15 – 17:30</td>
<td>BADGEM</td>
<td>Hall 5</td>
<td>Page 62-63</td>
</tr>
<tr>
<td>13:15 – 13:45</td>
<td>Keynote Lecture: Dr Chetan Mukhtyar</td>
<td>Hall 1</td>
<td>Page 64</td>
</tr>
<tr>
<td>13:45 – 14:25</td>
<td>Plenary Session</td>
<td>Hall 1</td>
<td>Page 64</td>
</tr>
<tr>
<td>14:25 – 15:10</td>
<td>Arthur Rook Oration: Professor Irwin McLean</td>
<td>Hall 1</td>
<td>Page 65</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Focus Session: Dermatomyositis: clinical phenotypes and associated autoantibodies</td>
<td>Hall 6</td>
<td>Page 66</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Focus Session: Management Controversies in SJS/TEN</td>
<td>Hall 10</td>
<td>Page 66</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Focus Session: Urticaria Past, Present and Future</td>
<td>Hall 9</td>
<td>Page 66</td>
</tr>
<tr>
<td>16:00 – 17:30</td>
<td>CPD update</td>
<td>Hall 1</td>
<td>Page 65</td>
</tr>
</tbody>
</table>
A LILLY SYMPOSIUM

UNCOVERING NEW PARADIGMS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS

WEDNESDAY 6 JULY / 13:00 – 14:00
HALL 10

96th Annual Meeting of the
British Association of Dermatologists
International Convention Centre, Birmingham
5 – 7 July 2016

13:00 – 13:10 Chair’s introduction
Dr Joyce Leman
Consultant Dermatologist, Scotland

13:10 – 13:30 New clinical approaches towards improving patient outcomes: rationale for IL-17A targeting
Prof. Frank Nestle
Professor of Molecular Dermatology MD, FMedSci, NIHR Senior Investigator, Guy’s, Kings College and St. Thomas’ Hospitals, London

Prof. Christopher Griffiths
Foundation Professor of Dermatology, MD, FRCP, FMedSci, The University of Manchester

13:50 – 14:00 Questions from the audience

If you would like to be kept informed of future Lilly events please register at: www.lillyregister.co.uk
Prescribing information can be found overleaf
Taltz, a targeted IL-17A inhibitor with high binding affinity (kd<3 pM)
Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

This medication is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.

Taltz® (Ixekizumab) ABBREVIATED PRESCRIBING INFORMATION
Presentation
Ixekizumab solution for injection in a pre-filled syringe or pre-filled pen. Each single use pre-filled syringe and pre-filled pen contains 80 mg of ixekizumab in 1 mL solution. The solution is clear and colourless to slightly yellow. Uses
Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Dosage and Administration
Posology
The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) at Weeks 2, 4, 6, 8, 10, and 12, then maintenance dosing of 80 mg (one injection) every 4 weeks. Consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment. Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks. Elderly: No dose adjustment is required. Renal or hepatic impairment: Taltz has not been studied in these patient populations. No dose recommendations can be made. Paediatric population: Taltz is for subcutaneous injection. Injection sites may be alternated. If possible, areas of the skin that show psoriasis should be avoided as injection sites. The solution/the syringe must not be shaken. After proper training in subcutaneous injection technique, patients may self-inject Taltz if a healthcare professional determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Comprehensive instructions for administration are given in the package leaflet. Contra-indications
Serious hypersensitivity to the active substance or to any of the excipients. Clinically important active infections (e.g. active tuberculosis). Warnings and Special Precautions
Infections: Treatment with Taltz is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections. Taltz should be used with caution in patients with clinically important chronic infection. If such an infection develops, monitor carefully and discontinue Taltz if the patient is not responding to standard therapy or the infection becomes serious. Taltz should not be resumed until the infection resolves. Taltz must not be given to patients with active tuberculosis (TB). Consider anti-TB therapy prior to initiation of Taltz in patients with latent TB. Hypermotility: Serious hypersensitivity reactions, including some cases of angioedema, urticaria and, rarely, late (10-14 days following injection) serious hypersensitivity reactions including widespread urticaria, dyspnea and high antibody titres have been reported. If a serious hypersensitivity reaction occurs, administration of Taltz should be discontinued immediately and appropriate therapy initiated. Inflammatory Bowel Disease: Cases of new or exacerbations of Crohn’s disease and ulcerative colitis have been reported. Caution should be exercised when prescribing Taltz to patients with inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, and patients should be monitored closely. Immunisations: Taltz should not be used with live vaccines. No data are available on the response to live vaccines: there are insufficient data on response to inactive vaccines. Excipients: This medicinal product contains less than 1 mmol sodium (23 mg) per 80 mg dose, i.e., essentially “sodium-free”. Please see Summary of Product Characteristics (SPC) for full information on excipients. Interactions
The safety of Taltz in combination with other immunomodulatory agents or phototherapy has not been evaluated. Fertility, Pregnancy, and Lactation
Women of childbearing potential: Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment. Pregnancy: It is recommended to avoid the use of Taltz during pregnancy. Breast-feeding: A decision should be made whether to discontinue breast-feeding or to discontinue Taltz. Fertility: The effect of ixekizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility. Effects on ability to drive and use machines Taltz has no or negligible influence on the ability to drive and use machines. Undesirable Effects
Summary of the safety profile: The most frequently reported adverse drug reactions were injection site reactions and upper respiratory tract infections (most frequently nasopharyngitis). Injection site reactions: The most frequent injection site reactions observed were erythema and pain. These reactions were predominantly mild to moderate in severity and did not lead to discontinuation of Taltz. Infections: In the placebo-controlled period of the phase III clinical studies in plaque psoriasis, infections were reported in 27.2% of patients treated with Taltz for up to 12 weeks compared with 22.9% of patients treated with placebo. The majority of infections were non-serious and mild to moderate in severity, most of which did not necessitate treatment discontinuation. Serious infections occurred in 13 (0.6%) of patients treated with Taltz and in 3 (0.4%) of patients treated with placebo. Very common (≥1/10): Upper respiratory tract infection, injection site reactions. Common (≥1/100 to <1/10): Tinea infection, oropharyngeal pain, nausea. For full details of these and other side-effects, please see the Summary of Product Characteristics, which is available at http://www.medicines.org.uk/emc/. Legal Category
POM Marketing Authorisation Numbers: EU/1/15/1085/002 EU/1/15/1085/004 Basic NHS Cost £2,250 per pack of 2 pre-filled pens £1,125 per pack of 1 pre-filled syringe Date of Preparation or Last Review April 2016 Full Prescribing Information is Available From Eli Lilly and Company Limited, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL Telephone: Basingstoke (01256) 315 000 E-mail: ukmedinfo@lilly.com TALTZ® (ixekizumab) is a registered trademark of Eli Lilly and Company.

If you are in the UK:
Adverse events should be reported. Reporting forms and further information can be found at: www.mhra.gov.uk/yellowcard. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000

If you are in the Republic of Ireland:
To report an adverse event or product complaint about a Lilly medication, please call Lilly Ireland on 01 664 0446. Adverse events and product complaints may also be reported to the Health Products Regulatory Authority. Reporting forms and information can be found at www.hpra.ie then click on ‘Report an Issue’
If you have booked your accommodation through Innov8 and have any issues they will be available to speak to directly on Tuesday. Please come to the registration area. Alternatively they can be contacted on 0844 887 1550.

We are pleased to announce that we will be providing a smartphone conference app for delegates to use during the conference. The app will provide the following features:

- Review agenda & speakers
- View abstracts & e-posters
- View sponsors & exhibitors

BAD 2016 is grateful to Janssen for sponsoring this app.

Conference badges will be handed to delegates on registration. For security purposes name badges must be worn at all times throughout the meeting. In the event that you lose your badge, a replacement must be obtained at the registration desk.

Please note that if you offer your badge barcode for scanning the company will receive your contact details.

ATM facilities are available in the Mall.

The Business Reception, located next to the Box Office on the Mall has a range of excellent business support services

Lunch and all scheduled refreshment breaks will be served from designated points in the exhibition area, Hall 3 of the ICC.

Certificates of attendance will be in your registration envelope.

The cloakroom is located in the Mall of the ICC, opposite Starbucks. There will be a charge of £1.00 per item.

This event is approved for external credit for the CPD scheme of the Federation of Royal Colleges of Physicians of the UK. Physicians should record their credits in their diaries, in accordance with the current RCP recommendations. Participants should only record the number of hours they attended. The main meeting has been approved for 18 credits and the CPD code is 105313.

The exhibition will be located in Hall 3 of the ICC and will be open at the following times:

- Tuesday 5th July: 10:00 – 17:00
- Wednesday 6th July: 09:00 – 17:30
- Thursday 7th July: 09:00 – 14:00

Exhibition quiz forms will be included in the delegate bags. To participate in the quiz, delegates must visit each participating exhibitor and answer a simple question. Participants must also obtain two answers from the patient support groups, please note you only need two from any of the patient support groups present over the duration of the meeting. All completed quiz forms must be returned to the registration desk by 14:00 on Thursday 7th July. The prizes will be announced after the meeting.

First aid support is available onsite; please ask an ICC host who will be able to assist you.

The nearest car parks to the ICC are located at sister venue the Barclaycard Arena. The North car park is closest or alternatively simply follow the road around on to St Vincent Street for the West car park or carry on further around to Sheeepcote Street for the South car park. Current charges are from £2.30 for up to 2 hours to £8.00 for 24 hours. Alternative parking is located at Brindley place or Paradise Circus.

We would prefer delegates to pay by cheque (pounds sterling drawn on a UK bank only or by sterling bank draft) made payable to the ‘British Association of Dermatologists’. Cheques in other currencies cannot be accepted. Alternatively, delegates may pay by credit card and this is encouraged for overseas delegates. Please note that we only accept MasterCard and Visa. American Express cannot be accepted.

The poster exhibition will be located in Hall 4 and on balcony of the exhibition hall. The posters will be numbered and a list is provided at the back of this programme.

There will be an e-poster display area showing all the posters submitted. Posters should be removed by 18:00 on Thursday 7th July. Please note that the British Association of Dermatologists cannot be held responsible for any loss or damage to a poster presented during the Annual Meeting.

The registration desk will be located centrally off the Mall and will be staffed by the BAD team during the following hours:

- Monday 4th July 09:00 – 18:00
- Tuesday 5th - Thursday 7th July 08:00 – 18:00

The following companies will be holding sponsored symposia at the meeting:

- 07:45 – 08:30 Hall 9  Celgene
- 07:45 – 08:30 Hall 10  LEO Pharma
- 13:00 – 14:00 Hall 10  Lilly
- 13:00 – 14:00 Hall 5  Sanoﬁ
- 18:15 – 19:00 Hall 9  Sobi
- 18:15 – 19:00 Hall 10  Bristol Myers Squibb

Speaker preview will be located in The Media Suite located near Hall 1, please ask at the registration desk for directions. All presenters must take their memory sticks to speaker preview at least two hours prior to their presentation. Data projection (PowerPoint) will be available.

Taxis are often parked outside the front of the ICC on Broad Street.

The International Convention Centre, Broad Street, Birmingham B1 2EA
General Enquiries: + 44 (0) 121 644 5025
www.theicc.co.uk

The BAD is pleased to introduce a well-being area within the Exhibition Hall. Therapists from D-Stress & Go (UK) www.dstress.co.uk are able to provide attendees with a wide variety of therapies which include Shiatsu, Reiki, Seated Acupressure Massage, Indian Head Massage and Thai Yoga Massage.

The free Wi-Fi network can be accessed in any part of the ICC, via an easy to use, quick, login page.
The ICC and Symphony Hall Layout

Key

A  Box Office/Business Reception
B  Starbucks
C  WH Smiths
D  Oak Kitchen
E  THSH Shop
F  Castle Fine Art

<table>
<thead>
<tr>
<th>Halls</th>
<th>Levels</th>
<th>Halls</th>
<th>Levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hall 1</td>
<td>4, 4a, 5, 5a, 6</td>
<td>Hall 9</td>
<td>2</td>
</tr>
<tr>
<td>Hall 3</td>
<td>4</td>
<td>Hall 10</td>
<td>2</td>
</tr>
<tr>
<td>Hall 3 Gallery</td>
<td>5</td>
<td>Hall 11</td>
<td>3</td>
</tr>
<tr>
<td>Hall 4</td>
<td>5</td>
<td>Symphony Hall</td>
<td>3, 4, 5, 5a</td>
</tr>
<tr>
<td>Hall 5</td>
<td>3, 4</td>
<td>Registration</td>
<td>4</td>
</tr>
<tr>
<td>Hall 6</td>
<td>3</td>
<td>Media Suite</td>
<td>4</td>
</tr>
<tr>
<td>Hall 7</td>
<td>4</td>
<td>Executive Rooms 1-6</td>
<td>5</td>
</tr>
<tr>
<td>Hall 8</td>
<td>5</td>
<td>Executive Rooms 7-10</td>
<td>5a</td>
</tr>
</tbody>
</table>

www.theicc.co.uk
Social Events

TRAINEE EVENING EVENT
4 July 2016, All Bar One Brindley place
17:30 - 21:00
The trainee evening event is a great opportunity to meet with colleagues and network in a relaxed and informal setting. Join us for drinks and food at All Bar One Brindley place.

SAS Evening Event
4 July 2016, Bank Restaurant & Bar
19:30 - 22:00
SAS Doctors are invited to an informal dinner on Monday evening.
This is a pre-booked event and tickets cost £10.00

BADfest
5 July 2016, ICC Birmingham
17:30 - 22:00
Bringing the spirit of a festival to the conference expect dazzling entertainment, street food and drinks. We hope this will be a perfect opportunity to relax, catch up with old acquaintances and form new friendships. This event will be taking place in hall 4 and surrounding areas of ICC Birmingham. All attendees are invited to attend.

BSDS Dinner
5 July 2016, Opus Restaurant
20:00 - 23:00
The British Society for Dermatological Surgery will hold a drinks reception followed by a fine dining meal at Opus Restaurant.
Ticket cost: £50.00 (reduced cost for trainees: £20.00)
Dress code: Black Tie

BSMD Curry night
6 July 2016, Asha’s
19:00 - 22:30
British Society for Medical Dermatology are hosting a curry night at Asha’s.
FULLY BOOKED
## Committee Meetings

### MONDAY 4 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING DETAIL</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 17:00</td>
<td>BJD Editorial Team Meeting</td>
<td>Executive 8</td>
</tr>
<tr>
<td>11:00 – 13:00</td>
<td>SAS Sub-committee</td>
<td>Executive 9</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>ISPD 2017 LOC</td>
<td>Executive 3</td>
</tr>
<tr>
<td>16:00 – 18:00</td>
<td>British Association of Dermatologists Officers</td>
<td>Executive 9</td>
</tr>
<tr>
<td>18:30 – 19:30</td>
<td>National Dermatology Trainee Committee</td>
<td>Hall 10</td>
</tr>
</tbody>
</table>

### TUESDAY 5 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING DETAIL</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 – 08:30</td>
<td>British Society for Dermatopathology Exec Committee</td>
<td>Executive 1</td>
</tr>
<tr>
<td>08:00 – 08:30</td>
<td>The British Society of Cutaneous Allergy (BSCA) AGM</td>
<td>Hall 9</td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td>Dermatology Industry Group</td>
<td>Executive 1</td>
</tr>
<tr>
<td>12:00 – 14:00</td>
<td>Community Dermatology</td>
<td>Executive 4</td>
</tr>
<tr>
<td>12:05 – 12:30</td>
<td>British Society for Skin Care in Immunocompromised Individuals AGM</td>
<td>Hall 10b</td>
</tr>
<tr>
<td>12:30 – 14:30</td>
<td>ESCD2016 Committee</td>
<td>Executive 2</td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>Health Informatics Sub-committee</td>
<td>Executive 8</td>
</tr>
<tr>
<td>15:30 – 16:30</td>
<td>Teachers of Undergraduate Dermatology</td>
<td>Executive 7</td>
</tr>
<tr>
<td>15:30 – 16:15</td>
<td>British Society for Dermatological Surgery AGM</td>
<td>Hall 5</td>
</tr>
<tr>
<td>15:45 – 16:15</td>
<td>British Society for Dermatopathology AGM</td>
<td>Hall 10a</td>
</tr>
<tr>
<td>16:00 – 17:00</td>
<td>Therapy &amp; Guidelines Sub-committee</td>
<td>Executive 8</td>
</tr>
<tr>
<td>17:15 – 18:45</td>
<td>British Association of Dermatologists’ AGM (Members Only)</td>
<td>Hall 1</td>
</tr>
</tbody>
</table>

### WEDNESDAY 6 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING DETAIL</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:00</td>
<td>Skin Cancer Prevention Sub-committee meeting</td>
<td>Executive 8</td>
</tr>
<tr>
<td>08:00 – 09:00</td>
<td>BJD Editorial Board Meeting</td>
<td>Executive 7</td>
</tr>
<tr>
<td>08:30 – 10:30</td>
<td>British Skin Foundation Grants Advisory</td>
<td>Executive 5</td>
</tr>
<tr>
<td>09:00 – 11:00</td>
<td>British Society for Dermatological Surgery Committee</td>
<td>Executive 1</td>
</tr>
<tr>
<td>11:30 – 12:30</td>
<td>British Association of Dermatologists Officers</td>
<td>Executive 2</td>
</tr>
<tr>
<td>12:15 – 12:45</td>
<td>British Cosmetic Dermatology Group AGM</td>
<td>Hall 8a</td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>British Society for Medical Dermatology Committee</td>
<td>Executive 8</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>British Association of Dermatologists’ Executive Committee</td>
<td>Hall 8b</td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td>Clinical Experimental Dermatology</td>
<td>Executive 2</td>
</tr>
<tr>
<td>16:00 – 18:00</td>
<td>British Society for Investigative Dermatology Committee</td>
<td>Executive 7</td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td>British Teledermatology Society AGM</td>
<td>Hall 10</td>
</tr>
<tr>
<td>16:30 – 17:15</td>
<td>Historical Collection Sub-Committee</td>
<td>Executive 2</td>
</tr>
</tbody>
</table>

### THURSDAY 7 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING DETAIL</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 – 08:15</td>
<td>British Society for Paediatric Dermatology Training Committee</td>
<td>Executive 1</td>
</tr>
<tr>
<td>08:30 – 09:30</td>
<td>Exhibitors’ Meeting</td>
<td>Executive 2</td>
</tr>
<tr>
<td>08:30 – 09:30</td>
<td>UK DCTN Trial Prioritisation Panel</td>
<td>Executive 8</td>
</tr>
<tr>
<td>10:00 – 11:00</td>
<td>BADGEM Steering Group Meeting</td>
<td>Executive 7</td>
</tr>
<tr>
<td>11:45 – 12:15</td>
<td>British Photodermatology Group AGM</td>
<td>Hall 9</td>
</tr>
<tr>
<td>12:15 – 13:15</td>
<td>British Hair and Nail Society Committee</td>
<td>Executive 2</td>
</tr>
<tr>
<td>12:15 – 13:45</td>
<td>UK Dermatology Clinical Trials Network AGM</td>
<td>Executive 1</td>
</tr>
<tr>
<td>12:15 – 13:15</td>
<td>BADGEM Informatics sub-group meeting</td>
<td>Executive 7</td>
</tr>
<tr>
<td>15:30 – 17:00</td>
<td>British Photodermatology Group Committee</td>
<td>Executive 2</td>
</tr>
<tr>
<td>17:15 – 18:15</td>
<td>British Society for Paediatric Dermatology Committee</td>
<td>Executive 1</td>
</tr>
</tbody>
</table>
## Monday 4 July Overview

### MONDAY 4 JULY 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION DETAIL</th>
<th>ROOM</th>
<th>INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 – 18:15</td>
<td>BSD Self-Assessment</td>
<td>Executive 2</td>
<td>Page 14</td>
</tr>
<tr>
<td>12:15 – 18:00</td>
<td>Trainee Pre-conference Session</td>
<td>Hall 5</td>
<td>Page 15</td>
</tr>
<tr>
<td>12:15 – 17:35</td>
<td>Staff &amp; Associate Specialist Session</td>
<td>Hall 8a</td>
<td>Page 16</td>
</tr>
</tbody>
</table>
4th BSD Dermatopathology Self Assessment

Date: Monday 4 July
Time: 12:45-18:15
Room: Executive 2
Chair: Dr Asok Biswas

Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 – 13:45</td>
<td>Lunch</td>
<td>Executive 1</td>
</tr>
<tr>
<td>13:45 – 15:45</td>
<td>Presentation of Cases 1 - 20</td>
<td></td>
</tr>
<tr>
<td>15:45 – 16:15</td>
<td>Break</td>
<td>Executive 1</td>
</tr>
<tr>
<td>16:15 – 18:15</td>
<td>Presentation of Cases 21 - 40</td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td>Evaluation forms, certificates and end of session</td>
<td></td>
</tr>
</tbody>
</table>

Royal College of Pathologists approved for CPD maximum of 6 credits

Speakers:
- Ruth Asher
- Sara Edward
- Asok Biswas
- Luisa Motta
- Rino Cerio
- Catherine Stefanato
- Peter Colloby
- Saleem Taibjee
- Paul Craig
- Maureen Walsh

Notes
Trainee Session

Date: Monday 4th July  
Time: 12:15-18:00  
Room: Hall 5  
Chairs: Dr Vincent Li and Dr David de Berker

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:15 – 12:55 | Lunch  
| 12:55 – 13:00 | Welcome and Introduction  
|             | Dr Vincent Li and Dr David de Berker                                  |
| 13:00 – 13:35 | TPC01  
|             | Dermatopathology Quiz  
|             | Dr Richard Carr                                                       |
| 13.35 – 14.05 | TPC02  
|             | Complex Medical Dermatology  
|             | Dr Cameron Kennedy                                                    |
| 14:05 – 14:50 | TPC03  
|             | HIV and the Skin  
|             | Professor Kieron Leslie                                                |
| 14:50 – 15:20 | TPC04  
|             | Tips for Trainee Dermatological Surgeons  
|             | Dr Richard Motley                                                     |
| 15:20 – 15:30 | TPC05  
|             | Trainee Update  
|             | Dr Vincent Li                                                         |
| 15:30 – 15:45 | Break  
|             | Hall 5 Foyer                                                          |
| 15:45 – 16:15 | TPC06  
|             | Updates: Hair Disorders  
|             | Dr Vicky Jolliffe                                                     |
| 16:15 – 16:45 | TPC07  
|             | Updates: Nail Disorders  
|             | Dr David de Berker                                                    |
| 16:45 – 17:15 | TPC08  
|             | Cosmetic Dermatology  
|             | Dr Tamara Griffiths                                                   |
| 17:15 – 18.00 | TPC09  
|             | The Next Step... Preparing to be a Dermatology Consultant  
|             | Dr Clare Defty and Dr James Halper                                     |
| 18:00 – 21:00 | Trainee evening event @ All Bar One                                    |

NOTES
Speciality & Associate Specialists Session

Date: Monday 4th July  
Time: 12:15-17:35  
Room: Hall 8a  
Chair: Dr Ausama Atwan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 – 13:00</td>
<td>Lunch</td>
<td>Hall 8b</td>
</tr>
<tr>
<td>13:00 – 13:05</td>
<td>Welcome and Introduction</td>
<td>Dr Jui Vyas</td>
</tr>
<tr>
<td>13:05 – 13:45</td>
<td>SAS01 Updates on the management of Hidradenitis Suppurativa</td>
<td>Dr John Ingram</td>
</tr>
<tr>
<td>13:45 – 14:25</td>
<td>SAS02 Facial Aesthetics</td>
<td>Dr Maria Gonzalez</td>
</tr>
<tr>
<td>14:25 – 15:05</td>
<td>SAS03 Practical Dermatopathology for Clinicians, a case based approach</td>
<td>Dr Victoria Swale</td>
</tr>
<tr>
<td>15:05 – 15:35</td>
<td>Break</td>
<td>Hall 8b</td>
</tr>
<tr>
<td>15:35 – 16:15</td>
<td>SAS04 Ethnic Hair: Problems and Solutions</td>
<td>Dr Ophelia Dadzie</td>
</tr>
<tr>
<td>16:15 – 16:55</td>
<td>SAS05 Purpura in children</td>
<td>Dr Manju Kalavala</td>
</tr>
<tr>
<td>16:55 – 17:35</td>
<td>SAS06 Pearls and pitfalls of Teledermatology</td>
<td>Dr Carolyn Charman</td>
</tr>
<tr>
<td>17:35</td>
<td>Closing Remarks</td>
<td></td>
</tr>
<tr>
<td>19:30 – 22:00</td>
<td>SAS evening event @ Bank Restaurant (pre-booked only)</td>
<td></td>
</tr>
</tbody>
</table>

NOTES
# Tuesday 5 July Overview

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION DETAIL</th>
<th>ROOM</th>
<th>INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 12:00</td>
<td>British Society of Cutaneous Allergy</td>
<td>Hall 9</td>
<td>Page 18-19</td>
</tr>
<tr>
<td>08:45 – 10:23</td>
<td>Clinicopathological Cases</td>
<td>Hall 1</td>
<td>Page 20</td>
</tr>
<tr>
<td>08:45 – 16:15</td>
<td>British Society for Dermatological Surgery</td>
<td>Hall 5</td>
<td>Page 21-23</td>
</tr>
<tr>
<td>09:00 – 12:30</td>
<td>British Society for Skin Care in Immunocompromised Individuals</td>
<td>Hall 10b</td>
<td>Page 24-25</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>10:40 – 10:55</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>11:00 – 16:15</td>
<td>British Society for Dermatopathology</td>
<td>Hall 1</td>
<td>Page 26-27</td>
</tr>
<tr>
<td>12:15 – 13:00</td>
<td>Pharma Presentations</td>
<td>Exhibition Hall</td>
<td>Page 67</td>
</tr>
<tr>
<td>12:15 – 14:30</td>
<td>THESIS working lunch - open to all</td>
<td>Executive 7</td>
<td>Page 28</td>
</tr>
<tr>
<td>13:00 – 14:35</td>
<td>BSACI Guest Society Session</td>
<td>Hall 9</td>
<td>Page 29</td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td>Senior Skin Group</td>
<td>Hall 10b</td>
<td>Page 30</td>
</tr>
<tr>
<td>13:15 – 14:15</td>
<td>Dermatology Teachers</td>
<td>Hall 10a</td>
<td>Page 31</td>
</tr>
<tr>
<td>14:30 – 15:00</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>14:40 – 14:55</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Keynote Lecture: Professor Martin Cook</td>
<td>Hall 1</td>
<td>Page 32</td>
</tr>
<tr>
<td>15:30 – 16:30</td>
<td>Plenary Session</td>
<td>Hall 1</td>
<td>Page 32</td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td>Keynote Lecture: Professor Michael Veness</td>
<td>Hall 1</td>
<td>Page 32</td>
</tr>
<tr>
<td>17:15 – 18:45</td>
<td>AGM – BAD members only</td>
<td>Hall 1</td>
<td></td>
</tr>
<tr>
<td>17:30 – 22:00</td>
<td>BADfest</td>
<td>Hall 4</td>
<td>Page 11</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 – 08:30</td>
<td>AGM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 – 09:00</td>
<td>Prosser White Oration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Translational Contact Dermatitis: From Bench to Clinic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Professor Thomas Rustemeyer (Amsterdam, The Netherlands)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 – 09:10</td>
<td>CD01, Eyelid dermatitis revisited: an evaluation of 231 patch test</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>patients over a 3-year period</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Lloyd-Lavery and S.M. Cooper</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:10 – 09:20</td>
<td>CD02, Isocyanate contact dermatitis: an unusual occupational source of</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>exposure</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.H. Foo and D.A. Thompson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:20 – 09:30</td>
<td>CD03, Dressings: an emerging source of acrylate contact allergy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Spencer, P. Gazzani and D.A. Thompson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 – 09:40</td>
<td>CD04, Perspectives on patch testing to pedometers, Perspex and other</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>plastic products: inert acrylate plastics as a source of allergic</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>contact dermatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Spencer, P. Gazzani and D.A. Thompson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:40 – 09:50</td>
<td>CD05, Twelve-year data of contact allergy to ethylenediamine dihydro</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>chloride: is it time to update the British Society for Cutaneous</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allergy baseline series?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Mirhadi and D.A. Thompson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:50 – 10:00</td>
<td>CD06, National U.K. patch testing data: what is the ideal proportion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>of the population that should be tested</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Keegan, B. Bhowry and A. Mughal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:10</td>
<td>CD07, Is there a role for standardizing contact allergy testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>services in England?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Chinthapalli, S. Ziaj and K. Gibbon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10 – 10:20</td>
<td>CD08, Photoinduced and photoaggravated allergic contact dermatitis due</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>to methylisothiazolinone</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Trokoudes, J. McFadden, R. Sarkany and P. Banerjee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20 – 10:30</td>
<td>CD09, Contact allergy to adipic acid and phthalic anhydride</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N. Bansal and D.A. Thompson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 – 11:20</td>
<td>Break, Guest lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Diagnosing Allergic Contact Dermatitis….the ‘Friday’ Method</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr John McFadden (London)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:20 – 11:30</td>
<td>CD10, Patch testing in patients with reactions to red tattoo pigment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Fleming and P. Todd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 – 11:40</td>
<td>CD11, Azathioprine does not influence the patch test reactivity in</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>contact dermatitis to weed parthenium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>K. Verma, N. Bhari and G. Sethuraman</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:40 – 11:50</td>
<td>CD12, Dermatology trainee contact dermatitis survey 2015</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Keith and J. Sansom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50 – 12:00</td>
<td>CD13, Allergic contact dermatitis to limonene and linalool in ironing</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>water</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Duhovic and C. Reckling</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**POSTERS**

CD14, Occupational allergic contact dermatitis to abacavir
A. Khalid and S. Ghaffar

CD15, A cautionary tale: history of a latex and rubber accelerator allergy misinterpreted as only latex allergy during a dental procedure
S. Gaikwad, R. Sabroe and C. Holden

CD16, Lichenoid oral eruption: a case of contact allergy to a cinnamon-flavoured toothpaste
A.R. Madineni and D.A. Thompson

CD17, Patch testing in pruritus ani and pruritus vulvae
M.-L. Lovgren, D. Torley and F.A. Campbell

CD18, Pigment-selective autoeczematization as a clue to allergic tattoo reactions
C. Fleming, J. Thomas, S.K. Chan and P. Todd
| CD19 | Evaluation of the effect of betamethasone on patch test reactivity in patients with contact dermatitis due to plant parthenium  
K. Verma and N. Bhari |
| CD20 | To bee or not to bee? A case of contact cheilitis to bee glue and lip balm allergens  
A. Cuell and D.A. Thompson |
| CD21 | Bisulfite sensitivity masquerading as a local anaesthetic allergy  
S. Sanyal and D.A. Thompson |
| CD22 | Contact allergy in children referred for patch testing  
R. Atkar and P. Todd |
| CD23 | Chasing the Pot of Gold  
E. Trowbridge, T. Fenton and V. Scott-Lang |
| CD24 | Severe exfoliative fingertip dermatitis second to goserelin acetate, exacerbated by contact allergy to 1,6-hexanediol diacrylate  
L. Nestor, S. White, J. Walshe and A. Lally |
| CD25 | Acute generalized exanthematous pustulosis due to dextromethorphan  
R.S. Rashid, T. Shim and I. Ahmed |
| CD26 | Tretinoin in bleaching creams: more than only an irritant?  
C. Leitner and D.A. Thompson |

*The poster viewing session will take place during the lunchbreak on Tuesday 5th July*

NOTES
Clinicopathological Cases
Joint meeting with the British Society of Dermatopathology

Date: Tuesday 5th July
Time: 08:45-10:23
Room: Hall 1
Chairs: Professor Rino Cerio & Dr Sara Edward

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 – 08:52</td>
<td>CPC01</td>
<td>Adult-onset folliculocentric Langerhans cell proliferation of uncertain malignant potential</td>
<td>J. Li Chun Wong, R. Parslew, N. Stefanos, A. Biswas and A. Bakshi</td>
</tr>
<tr>
<td>08:52 – 08:59</td>
<td>CPC02</td>
<td>A tropical ‘mole’</td>
<td>A. Godwin, PD Yesudian and A. Bansal</td>
</tr>
<tr>
<td>08:59 – 09:06</td>
<td>CPC03</td>
<td>Systemic lupus erythematosus presenting with a neutrophilic dermatoses</td>
<td>A. Lee, L. Igali and A.M. Skellett</td>
</tr>
<tr>
<td>09:13 – 09:20</td>
<td>CPC05</td>
<td>Tattoo-like macular blue skin lesions in a tyre factory worker exposed to carbon black</td>
<td>M. Al Abadie, D. Karunaratne, A.C.F. Juana, S. Amar and N. Salmons</td>
</tr>
<tr>
<td>09:20 – 09:27</td>
<td>CPC06</td>
<td>Visage mauve</td>
<td>N. Spierings, S. Al-Hyassat and N. Cowley</td>
</tr>
<tr>
<td>09:27 – 09:34</td>
<td>CPC07</td>
<td>A dramatically different case of Dowling–Degos disease</td>
<td>N. Spierings, H. Chong, R. Betz and M. Singh</td>
</tr>
<tr>
<td>09:41 – 09:48</td>
<td>CPC09</td>
<td>Angioimmunoblastic T-cell lymphoma masquerading as drug reaction with eosinophilia and systemic symptoms</td>
<td>D. O’Callaghan, J. Felton, D. Wright and A. Attygalle</td>
</tr>
<tr>
<td>09:55 – 10:02</td>
<td>CPC11</td>
<td>A vesiculobullous crusted eruption in a quadriplegic long-term care patient</td>
<td>J. Boggs, L. Tobbia and M. O’Kane</td>
</tr>
<tr>
<td>10:02 – 10:09</td>
<td>CPC12</td>
<td>Postirradiation atypical vascular proliferation following breast-conserving therapy for breast carcinoma</td>
<td>R. Anand, F. Kubba, J. Vaidya and K. Taghipour</td>
</tr>
</tbody>
</table>
British Society for Dermatological Surgery

Date: Tuesday 5th July
Time: 08:45-16:15
Room: Hall 5
Chairs: Dr Stephen Keohane & Dr Raj Mallipeddi
Dr Vindy Ghura & Dr Chris Bower
Dr Raj Mallipeddi

PROGRAMME

08:45 – 08:52 DS01 Proposal for National Dermatology Surgery Safety Standards: development of a dermatology surgery standard operating policy with mandatory training of staff may be an important tool to prevent wrong-site surgery
R. Bhutani, C. Machin, G. Stables, V. Goulden and A. Mitra

08:52 – 08:59 DS02 Dermatology surgery consent photo booklet enhances patient satisfaction
N.R. Arujuna, L. Brendling and C. DeGiovanni

08:59 – 09:06 DS03 Preliminary data and the design of a new U.K.-wide trial (Rational MCC) comparing surgery vs. radiotherapy as the first definitive treatment for primary Merkel cell carcinoma
C. Harwood, C. Yap, J. Marsden, O. Cassell, C. Corner, P. Lawton, M. Moncrieff, H. Peach, C. Proby, R. Blundred, S. Rodwell and N. Steven

09:06 – 09:13 DS04 Feasibility of a trial investigating the management of primary cutaneous squamous cell carcinoma (SCC): COventional vs. Mohs MIcrographic Surgery for high-risk SCC with or without Adjuvant Radiotherapy (COMMISSAR)

09:13 – 09:20 DS05 Final outcomes for surgical management of dermatofibrosarcoma protuberans: a 10-year review of clinical practice in the U.K.

09:20 – 09:27 DS06 Microretrodermal axillary curettage effectively reduces axillary hyperhidrosis
D. Vakili and D. Baker

09:27 – 09:34 DS07 miraDry®: a novel noninvasive permanent treatment for axillary hyperhidrosis
S. Nassar, F. Teixeira, S. Punjabi, A. Charikida, B. Brazzini and A. Chu

09:34 – 09:41 DS08 The use of a novel 1-hour protocol for rapid frozen-section immunocytochemistry, in a case of squamous cell carcinoma treated with Mohs micrographic surgery
K. Sinha, F. Ali, R. Patilay, R. Mallipeddi and G. Orchard

09:41 – 09:48 DS09 Advanced basal cell carcinomas treated by vismodegib and Mohs micrographic surgery: does neoadjuvant treatment have a role?
S. Brown, D. Brass, N. Rajan, T. Oliphant, R. Plummer and J. Langtry

09:48 – 09:55 DS10 Factors associated with recurrence and metastasis in primary cutaneous squamous cell carcinoma of the pinna: a 3-year retrospective study and meta-analysis
M. Khan, J. Stansfield and S. Khwaja

09:55 – 10:02 DS11 QUICK FIRE RECON
The offset Z-plasty transposition flap: a useful option in cutaneous reconstruction
S.-A. Ho and A. Affleck

10:02 – 10:09 DS12 QUICK FIRE RECON
When less is more: effective outcomes of shorter single-arm advancement flaps with periosteal tacking sutures for medial canthal repair
F.R. Ali and R. Mallipeddi

10:09 – 10:16 DS13 QUICK FIRE RECON
Helical rim reconstruction utilizing a postauricular interpolation flap
P.S. Jayasekera, L. Naysmith, T.J. Oliphant, C. Lawrence and J.A.A. Langtry

10:16 – 11:00 Break Exhibition Hall

11:00 – 11:07 DS14 A multicentre study of patient-reported outcomes in relation to Mohs micrographic surgery across two tertiary centres in the U.K.
V. Prince, S. Rai, N. Telfer and V. Ghura

11:07 – 11:14 DS15 Portable negative-pressure wound therapy for management of poorly healing wounds
S. Menzies, E. McGrath, B. Wynne, P. Ormond and R. Barry

11:14 – 11:21 DS16 Long-term follow-up of imiquimod-treated lentigo maligna
M. Papanikolaou and C.M. Lawrence

11:28 – 11:35 DS24 QUICK FIRE RECON Medial canthal webbing following skin cancer surgery reconstruction revised with Z-plasty in 14 patients
K. Kazmierczyk, T. Oliphant and J. Langtry

11:35 – 11:42 DS25 QUICK FIRE RECON A turnover island pedicle flap as a single-stage novel reconstructive method of deep complex defects involving the nasal vestibule and ala
V. Prince and S. Rai

11:42 – 11:49 DS20 Safe treatment of truncal compensatory hyperhidrosis with high-dose botulinum neurotoxin A over 5 years
N. Spierings and C. Harland

11:49 – 11:56 DS21 Impact of a diagnostic biopsy on the management of patients with suspected basal cell carcinomas treated with Mohs micrographic surgery
A.P. Panthagani, E. Natafji, L. Naysmith and S. Rice

11:56 – 12:03 DS22 World Health Organization surgical checklist in dermatological surgery: compliance, attitudes and barriers
T.M. Tian, L. Myers, P. Bogucki, A. Bray and D. de Berker

12:03 – 12:10 DS23 Increasing trend of aggressive nonmelanoma skin cancer in a young population
A. Flynn, B. Wynne, P. Ormond and R. Barry

12:10 – 12:17 DS18 Pulsed-dye laser and topical cantharidin for the treatment of recalcitrant cutaneous warts
P. Saraogi and V. Madan

12:17 – 12:24 DS19 Carbon dioxide laser treatment for recalcitrant viral warts: a case series
Z. Laftah and S.J. Bashir

12:24 – 12:31 DS26 Study to assess recurrence rates and patient satisfaction postradiotherapy for head and neck basal cell carcinomas
S. Momen, E. Craythorne and T. Guerrero Urbano

12:31 – 13:30 Lunch Exhibition Hall

FOCUS SESSION

13:30 – 14:15 The avoidance and management of common problems in dermatological surgery
Dr Rupert Barry (Dublin, Ireland)

14:15 – 14:45 Guest Lecture
Radiotherapy and my patient with skin cancer: Why and when should I refer them on to a Radiation Oncologist?
Professor Michael Veness (Sydney, Australia)

In the Australian setting of endemic skin cancer radiotherapy is a well-established non-surgical modality that is utilised in many patients with skin cancer. The clinical scenarios where radiotherapy may benefit a patient are varied and range from: as an alternative to surgery (e.g. nasal tip BCC, lower lip SCC), adjuvant treatment in patients with high-risk cancers (e.g. positive margin, presence of PNI) and in the palliative setting (incurable and elderly). An appreciation of when a patient should be sent to a radiation oncologist is important for all clinicians that manage these patients and can ultimately be of benefit to your patient. A series of clinical cases will be presented to illustrate the application of radiotherapy in skin cancer patients.

14:45 – 15:00
15:00 – 15:30 Break Exhibition Hall
Keynote Lecture: Professor Martin Cook – Hall 1

15:30 – 16:15 AGM

16:30 – 17:00 Keynote Lecture: Professor Michael Veness – Hall 1

POSTERS

DS27 Biopsies and incomplete excisions of melanoma in primary care: a review of our audits from 2006 to 2015
P. Gurung, R. Raghunath, N.C. Chetty and J. Garioch

DS28 Mohs micrographic surgery is the required treatment for periocular microcystic adnexal carcinoma to maximize the possibility of tumour clearance
T. Mestre, T. Oliphant, C. Lawrence, E. Barnes, L. Clarke, J. Dickinson and J. Langtry

DS29 Mohs micrographic surgery for the treatment of vulval basal cell carcinoma
A. Abdul-Wahab, K. Sinha, E. Calonje, F. Lewis and E. Craythorne

DS30 Carcinoma of the distal nasal mucosa: beware the tip of the iceberg...
M. Ferguson, A. Affleck, S. Laverick and A. Evans
<table>
<thead>
<tr>
<th>DS31</th>
<th>Incidence and risk factors of blood splatter in dermatological surgery: need for full facial protection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Aguilar-Duran, A. Panthagani, L. Naysmith and A. Holme</td>
</tr>
<tr>
<td>DS32</td>
<td>A systematic review of thoracic sympathectomy to treat facial blushing</td>
</tr>
<tr>
<td></td>
<td>G. Girish, R.E. D’Souza, P. D’Souza and D. Baker</td>
</tr>
<tr>
<td>DS33</td>
<td>A rare case of melanoma presenting in the prostate</td>
</tr>
<tr>
<td></td>
<td>A. Wernham, G. Fremlin, P. Naidoo and I. Zaki</td>
</tr>
<tr>
<td>DS34</td>
<td>Does formal dermoscopy training reduce the number needed to excise in melanoma treatment?</td>
</tr>
<tr>
<td></td>
<td>A. Riding, T. Oliphant and K. Blasdale</td>
</tr>
<tr>
<td>DS35</td>
<td>The golden goddess of spices: a cure for Bowen disease?</td>
</tr>
<tr>
<td></td>
<td>N. Harper, H. Saigal and S. Orpin</td>
</tr>
<tr>
<td>DS36</td>
<td>Feasibility analysis to evaluate the role of perioperative antibiotics in reducing infection rates in ulcerated skin cancers</td>
</tr>
<tr>
<td>DS37</td>
<td>Mohs micrographic surgery: the patient experience</td>
</tr>
<tr>
<td></td>
<td>A. Flynn, B. Wynne, P. Ormond and R. Barry</td>
</tr>
<tr>
<td>DS38</td>
<td>Hair transplantation to repair the eyebrow following Mohs micrographic surgery of basal cell carcinoma of the forehead and eyebrow</td>
</tr>
<tr>
<td></td>
<td>T.W. Siah, T. Oliphant and J. Langtry</td>
</tr>
<tr>
<td>DS39</td>
<td>Public awareness of skin cancer: results of a large national survey in Ireland</td>
</tr>
<tr>
<td></td>
<td>S. Menzies, H. Forristal, C. Hennessy, L. Yeates and P. Ormond</td>
</tr>
<tr>
<td>DS40</td>
<td>Factors predicting complex repair following skin cancer excision</td>
</tr>
<tr>
<td></td>
<td>D. Keith, P.K. Walker-Smith, H. Skalsky and A. Bray</td>
</tr>
<tr>
<td>DS41</td>
<td>Squamous cell carcinoma developing shortly after treatment with vismodegib in a patient with multiple basal cell carcinomas</td>
</tr>
<tr>
<td></td>
<td>P. Babakinejad, D. Jain, A. Bhat and M. Vatve</td>
</tr>
<tr>
<td>DS42</td>
<td>Electrosurgical resurfacing of rhinophyma: long-term follow-up, surgical outcomes and patient satisfaction</td>
</tr>
<tr>
<td></td>
<td>M. Papanikolau, T. Mestre, T. Oliphant, C.M. Lawrence and J. Langtry</td>
</tr>
<tr>
<td>DS43</td>
<td>Assessment of the efficacy of follicular unit extraction in the treatment of stable vitiligo: a pilot study</td>
</tr>
<tr>
<td></td>
<td>M. Thomas</td>
</tr>
<tr>
<td>DS44</td>
<td>Synchronous melanoma in patients with primary cutaneous malignant melanoma</td>
</tr>
<tr>
<td></td>
<td>F.C. Kreeshan and K. Blasdale</td>
</tr>
<tr>
<td>DS45</td>
<td>Diagnostic accuracy in pigmented lesions: further supportive evidence for consultant-led dermatology skin cancer services</td>
</tr>
<tr>
<td></td>
<td>A. Brown and E.J. McGrath</td>
</tr>
<tr>
<td>DS46</td>
<td>Complications in dermatological surgery: a single-centre experience</td>
</tr>
<tr>
<td></td>
<td>A. Khoo and E. Tan</td>
</tr>
<tr>
<td>DS47</td>
<td>Patient-reported outcomes and experience of Mohs surgery: a questionnaire study</td>
</tr>
<tr>
<td></td>
<td>O. Hameed, C. Archer and S. Felton</td>
</tr>
<tr>
<td>DS48</td>
<td>What comes through the Mohs clinic door?</td>
</tr>
<tr>
<td></td>
<td>F. Ferguson, Z. Yiu, V. Madan, N. Telfer and V. Ghura</td>
</tr>
<tr>
<td>DS49</td>
<td>A literature review assessing the benefit of sentinel lymph node biopsy in thin melanomas</td>
</tr>
<tr>
<td></td>
<td>H. Rivat</td>
</tr>
<tr>
<td>DS50</td>
<td>Multiple basal cell carcinomas arising within port-wine stains in patients treated with thorium X</td>
</tr>
<tr>
<td></td>
<td>G.A. Fremlin, A. Wernham, R. Muc, P. Colloby, I. Zaki and H. Al-Rawi</td>
</tr>
<tr>
<td>DS51</td>
<td>Multiple basal cell carcinomas of the nose treated by Mohs micrographic surgery in the same session and reconstruction of the resulting defects</td>
</tr>
<tr>
<td></td>
<td>P.S. Jayasekera, T.J. Oliphant and J.A.A. Langtry</td>
</tr>
<tr>
<td>DS52</td>
<td>Developing a Mohs micrographic surgery service: lessons learnt in the first 5 years</td>
</tr>
<tr>
<td></td>
<td>A. Zografou, E. McGrath and C. Bower</td>
</tr>
<tr>
<td>DS53</td>
<td>Following up patients with cutaneous squamous cell carcinoma: 5-year data from a tertiary university centre</td>
</tr>
<tr>
<td></td>
<td>M. Papanikolau, C.M. Lawrence, C. Blasdale and P.J. Hampton</td>
</tr>
<tr>
<td>DS54</td>
<td>The effect of a pigmented lesion clinic in the Mid-West of Ireland on melanoma diagnosis and management</td>
</tr>
<tr>
<td>DS55</td>
<td>Intraoral laser hair removal: can we call it permanent?</td>
</tr>
<tr>
<td></td>
<td>S. Sanyal and A. Abdullah</td>
</tr>
<tr>
<td>DS56</td>
<td>Excision of nonmelanoma skin cancers overlying an arteriovenous fistula</td>
</tr>
<tr>
<td></td>
<td>E. O’Brennan and A. Affleck</td>
</tr>
</tbody>
</table>

*The poster viewing session will take place between 12:45 and 13:15 on Tuesday 5th July*
### British Society for Skin Care in Immunocompromised Individuals

**Date:** Tuesday 5th July  
**Time:** 09:00 – 12:30  
**Room:** Hall 10b  
**Chairs:** Dr David Paige  
Dr Helen Ramsay

#### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:05</td>
<td>Welcome &amp; Introduction by Professor Charlotte Proby</td>
</tr>
</tbody>
</table>
| 09:05 – 09:10 | INTERACTIVE CASE DISCUSSION with Expert panel  
Dr John Lear, Dr Nilesh Morar, Dr Conal Perrett and Prof Catherine Harwood. |
| 09:10 – 09:15 | Cutaneous phaeohyphomycosis caused by *Biatriospora mackinnonii* in a renal transplant recipient  
H. Leeman, T. Bicanic, J. Popoola, C. Kaur and M. Singh |
| 09:15 – 09:20 | Cutaneous malakoplakia in an immunosuppressed patient  
S. Nasir, V. Van De Velde, M. Sheaff, R. Cerio, C. Nic Fhogartaigh, V. Jolliffe and C. Harwood |
| 09:20 – 09:25 | Fatal disseminated cowpox virus infection in an immunosuppressed adolescent  
| 09:25 – 09:30 | Discussion time                                                      |
| 09:30– 09:35 | Beware the rare mimicker: squamoid eccrine ductal carcinoma in a renal transplant recipient  
J. Thomson, R. Mokbel, D. Markiewicz, G. Moir, R. Cerio and C. Harwood |
| 09:35 – 09:40 | Post-transplant lymphoproliferative disorders presenting in the skin in renal transplant recipients  
| 09:40 – 09:45 | Jejunal perforation: an unusual presentation of metastatic cutaneous squamous cell carcinoma in an immunosuppressed patient  
R.M. Fisher, D. Warnapala, N. Hitchen, J. Dua, A. Freebairn and P. Pratsou |
| 09:45 – 09:50 | Catastrophic cutaneous carcinogenesis in a renal transplant recipient  
| 09:50 – 10:00 | Discussion time                                                      |
| 10:00 – 10:30 | Guest Lecture – Introduced by Professor Catherine Harwood  
Immunological factors that influence post-transplant skin cancer risk  
Dr Paul Harden (Oxford) |
| 10:30 – 11:15 | Break  
Exhibition Hall |
P. Doiron, N. Morar and C. Bunker |
| 11:20 – 11:25 | Severe and refractory psoriasis associated with myelodysplastic syndrome  
| 11:30 – 11:35 | Discussion time                                                      |
P. Gazzani and A. Martin-Clavijo |
| 11:45 – 11:55 | Patient evaluation of a dedicated dermatology service for stem cell transplant recipients  
using the Outcomes and Experiences Questionnaire  
R.N. Matin, A. Peniket, T. Littlewood, R. Danby and E. Gibbons |
| 11:55 – 12:05 | Induction of antihuman papilloma virus immunity by microwave treatment of skin.  
<p>| 12:05 – 12:30 | AGM |</p>
<table>
<thead>
<tr>
<th>POSTERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BI15</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI16</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI17</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI18</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI19</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI20</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI21</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI22</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI23</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI24</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI25</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI26</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI27</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI28</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI29</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI30</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI31</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>BI32</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

*The poster viewing session will take place during the morning coffee break on Tuesday 5th July*
**British Society for Dermatopathology**

**Date:** Tuesday 5th July  
**Time:** 11:00-16:15  
**Room:** Hall 1  
**Chairs:** Dr Paul Craig & Dr Asok Biswas

### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:05</td>
<td>Introduction and comments on posters</td>
</tr>
<tr>
<td>11:05 – 11:50</td>
<td>Joint BAD/BSD Neil Smith Lecture</td>
</tr>
<tr>
<td></td>
<td><strong>Does terminology matter in the management of melanocytic lesions.</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Professor Martin Cook (Guildford, UK)</strong></td>
</tr>
<tr>
<td></td>
<td>Terminology for melanocytic lesions is poorly defined and confusing and</td>
</tr>
<tr>
<td></td>
<td>presentations usually assume a common understanding of the various</td>
</tr>
<tr>
<td></td>
<td>terms. In practice one person's dysplastic naevus is another's compound</td>
</tr>
<tr>
<td></td>
<td>naevus. Even melanoma is spoken of as though it were one entity refined</td>
</tr>
<tr>
<td></td>
<td>only by thickness and mitoses. In contrast as a pathologist, it</td>
</tr>
<tr>
<td></td>
<td>seems almost as though each melanoma is a distinct entity in itself,</td>
</tr>
<tr>
<td></td>
<td>because of the considerable variation. Some classification into nodular</td>
</tr>
<tr>
<td></td>
<td>SSM, ALM and LMM is used commonly but it seems to have little influence</td>
</tr>
<tr>
<td></td>
<td>on management decisions. Should these classifications be maintained or</td>
</tr>
<tr>
<td></td>
<td>should we rely on a molecular signature?</td>
</tr>
<tr>
<td></td>
<td>The area of most confusion lies with terminology associated with spitzoid,</td>
</tr>
<tr>
<td></td>
<td>blue and deep penetrating naevi as well as the ubiquitous dysplastic</td>
</tr>
<tr>
<td></td>
<td>naevus. The observer agreement is poor and prognostic accuracy is</td>
</tr>
<tr>
<td></td>
<td>unreliable and therefore management decisions variable. There is scope</td>
</tr>
<tr>
<td></td>
<td>for much improvement in all these areas and achieving that should be a</td>
</tr>
<tr>
<td></td>
<td>reasonable expectation.</td>
</tr>
<tr>
<td>11:50 – 12:51</td>
<td>Lunch Exhibition Hall</td>
</tr>
<tr>
<td>12:51 – 13:00</td>
<td>DP01 Expression of programmed death-1 in cutaneous malignant melanoma</td>
</tr>
<tr>
<td></td>
<td>and its prognostic significance</td>
</tr>
<tr>
<td></td>
<td>B. Sim and S. Elsheikh</td>
</tr>
<tr>
<td>13:00 – 13:09</td>
<td>DP02 Spectrum of granuloma annulare: a retrospective clinicopathological</td>
</tr>
<tr>
<td></td>
<td>study</td>
</tr>
<tr>
<td></td>
<td>P. Saraogi, U. Khopkar and S. Mahajan</td>
</tr>
<tr>
<td>13:09 – 13:18</td>
<td>DP03 Malignant melanotic schwannian tumour: when it is just not quite</td>
</tr>
<tr>
<td></td>
<td>right for melanoma</td>
</tr>
<tr>
<td></td>
<td>K. Semkova and E. Calonje</td>
</tr>
<tr>
<td>13:18 – 13:27</td>
<td>DP04 Review of the histology in cases of clinically diagnosed lichen</td>
</tr>
<tr>
<td></td>
<td>sclerosus et atrophicus</td>
</tr>
<tr>
<td></td>
<td>Murphy</td>
</tr>
<tr>
<td>13:27 – 13:36</td>
<td>DP05 Pilar neurocristic hamartoma of the scalp: a case series</td>
</tr>
<tr>
<td></td>
<td>N. Mansoor, K. Han, R. Hambly, N. Ralph, K. Cronin, N. Mulligan and F.J.</td>
</tr>
<tr>
<td></td>
<td>Moloney</td>
</tr>
<tr>
<td>13:36 – 13:45</td>
<td>DP06 Lymphoepithelioma-like carcinoma of the skin: a diagnosis to</td>
</tr>
<tr>
<td></td>
<td>consider in the tumour clinic</td>
</tr>
<tr>
<td></td>
<td>Fraser</td>
</tr>
<tr>
<td>13:45 – 13:54</td>
<td>DP07 Granulomatous dermatitis: a novel cutaneous side-effect of</td>
</tr>
<tr>
<td></td>
<td>vemurafenib</td>
</tr>
<tr>
<td></td>
<td>E. Ong, R. Sinha and L. Fearfield</td>
</tr>
<tr>
<td>13:54 – 14:03</td>
<td>DP08 Neuroendocrine carcinoma <em>in situ</em> in association with Bowenoid</td>
</tr>
<tr>
<td></td>
<td>Epidermal dysplasia and squamous cell carcinoma</td>
</tr>
<tr>
<td></td>
<td>Y.W. Tsang, S. Taibjee, J. Carter and R. Carr</td>
</tr>
<tr>
<td>14:03 – 14:09</td>
<td>DP09 The evolution of histopathological changes in dermatitis artefacta</td>
</tr>
<tr>
<td></td>
<td>D. O’Callaghan, D. Markiewicz, S. Shinhmar and A. Bewley</td>
</tr>
<tr>
<td>14:09 – 14:15</td>
<td>DP10 Two cases of panniculitis secondary to alpha-1-antitrypsin deficiency</td>
</tr>
<tr>
<td></td>
<td>E. Storan, S. O’ Gorman, L. Aalto, A. Murphy and T. Markham</td>
</tr>
<tr>
<td>14:15 – 14:21</td>
<td>DP11 Gryzbowski syndrome redefined: are we missing the bigger picture?</td>
</tr>
<tr>
<td></td>
<td>K. Semkova, H. Cooper, S. Gamboni and E. Calonje</td>
</tr>
<tr>
<td>14:21 – 14:27</td>
<td>DP12 Angioinvasive lymphomatoid papulosis: a rare subtype easily</td>
</tr>
<tr>
<td></td>
<td>mistaken for a high-grade angioinvasive lymphoma</td>
</tr>
<tr>
<td></td>
<td>P. Trehan, A. Bakshi, M. Walsh and R. Azurdia</td>
</tr>
<tr>
<td>14:27 – 15:00</td>
<td>Break Exhibition Hall</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Keynote Lecture: Professor Martin Cook – Hall 1</td>
</tr>
<tr>
<td>15:45 – 16:15</td>
<td>AGM – Hall 10a</td>
</tr>
<tr>
<td>Poster</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>DP13</td>
<td>A case of a curious itch</td>
</tr>
<tr>
<td>DP14</td>
<td>Myofibroma: a 10-year experience in a tertiary referral hospital</td>
</tr>
<tr>
<td>DP15</td>
<td>Take a second look: a challenging case of non-Langerhans cell histiocytosis</td>
</tr>
<tr>
<td>DP17</td>
<td>Mixed immunobullous disease</td>
</tr>
<tr>
<td>DP19</td>
<td>A long-standing large leg ulcer in a patient with Schöpf–Schulz–Passarge syndrome</td>
</tr>
<tr>
<td>DP20</td>
<td>An unusual skin malignancy</td>
</tr>
<tr>
<td>DP21</td>
<td>Erythema gyratum repens in association with inflammatory epidermolysis bullosa acquisita</td>
</tr>
<tr>
<td>DP22</td>
<td>Elastotic nodules of the ears: a forgotten differential?</td>
</tr>
<tr>
<td>DP23</td>
<td>Widespread tattoo sarcoidosis</td>
</tr>
<tr>
<td>DP24</td>
<td>Bringing Kikuchi–Fujimoto disease to light</td>
</tr>
<tr>
<td>DP25</td>
<td>Primary cutaneous apocrine carcinoma or metastatic breast carcinoma?</td>
</tr>
</tbody>
</table>

The poster viewing session will take place during the lunch break on Tuesday 5th July.
THESIS Working Lunch – open to all

Date: Tuesday 5th July
Time: 12:15 -14:30
Room: Executive 7
Chair: Dr Michael Ardern-Jones

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 – 12:30</td>
<td>The Skin Investigation Society</td>
<td>Dr Michael Ardern-Jones (Southampton)</td>
</tr>
<tr>
<td>12:30 – 13:00</td>
<td>Clinical research</td>
<td>Professor Catherine Smith (London)</td>
</tr>
<tr>
<td>13:00 – 13:30</td>
<td>Lab based research</td>
<td>Professor Eugene Healy (Southampton)</td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td>How to make research happen</td>
<td>Professor Charlotte Proby (Dundee)</td>
</tr>
<tr>
<td>14:00 – 14:30</td>
<td>How to get published</td>
<td>Professor Alex Anstey (Bangor)</td>
</tr>
</tbody>
</table>

NOTES

---

---

---

---

---

---

---

---
BSACI Guest Society Session

Date: Tuesday 5th July
Time: 13:00-14:35
Room: Hall 9
Chairs: Dr Helen A Brough & Dr Carsten Flohr

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:05</td>
<td>Welcome – Dr Nick Levell</td>
</tr>
</tbody>
</table>
| 13:05 – 13:30 | The interaction between skin barrier function and immunology in atopic eczema  
Professor Donald Leung (Denver, USA) |
| 13:30 – 13:55 | Microbes, milk and moisturisers - how to stop infants developing eczema  
Dr Robert Boyle (London) |
| 13:55 – 14:35 | Pro Con debate: Dietary manipulation is more important than steroids in infants with eczema?  
Pro: Dr Adam Fox (London) 
Con: Dr David Atherton (London) |

NOTES
Dermatological Research in the Elderly in New Zealand
Dr Paul Jarrett (Auckland, New Zealand)

Can a psychological intervention to reduce stress alter the physical process of wound healing in the elderly? Are physically and or cognitively impaired elderly more or less likely to suffer dermatological disease compared to their more able counterparts?

Expressive writing is an intervention with demonstrated benefits on psychological and physical health. 49 older adults were asked to write for 20 minutes a day for 3 days. One group wrote about upsetting life events (Expressive writing) and the control group about daily activities (Time management). Two weeks after writing a 4mm punch biopsy was taken from the inner upper arm and the wound healing was monitored for 21 days. At day 11 post biopsy, the Expressive writing group had a greater proportion of fully re-epithelialised wounds compared to the Time management group (p=0.028). More sleep in the week prior to wounding predicted faster healing wounds. This simple intervention, appropriate for an older age group, may have clinical implications for wound healing in the elderly. (Psychosom Med 2013; 75; 581-90).

Eighty-eight rest home or hospital level care residents, in two residential care facilities in South Auckland, underwent a skin examination. Concurrently, their physical and cognitive ability was assessed. The most common clinical finding was onychomycosis 42 (47.7%) and basal cell carcinoma 13 (14.8%). Additionally, melanoma 2 (2.3%), squamous cell carcinoma 7 (8%) and carcinoma of the breast 1 (1.1%) were detected. Inflammatory dermatological disease was more common in those with little physical disability compared with serious physical disability (p=0.04). No significant association was found between dermatological disease and cognitive impairment. Possibly, those residents receiving a higher level of attention by attending staff, because of physical disability, had a greater level of incidental observation and therefore treatment of dermatological inflammatory disease. (BMJ Open 2015 doi:10.1136/bmjopen-2015-009941).
Dermatology Teachers

Date: Tuesday 5th July
Time: 13:15-14:15
Room: Hall 10a
Chair: Dr Mini Singh

**PROGRAMME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 – 13:45</td>
<td>DT02</td>
<td>Does Precision Teaching enhance dermatology diagnostic skills in medical students?</td>
<td>C. McGrath, C. McCourt, G. Gormley, K. Dillenburger, K. Dounavi and A. Corry</td>
</tr>
<tr>
<td>13:45 – 14:00</td>
<td>DT03</td>
<td>A visual literacy course for dermatology trainees</td>
<td>L. Griffin, N.Y.Z. Chiang, H. Tomlin, H. Young and C.E.M. Griffiths</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>DT04</td>
<td>Updating the curriculum content for undergraduate dermatology education</td>
<td>S. Cohen, A. Ascott, A. Honan, S. Ogilvie, M. Sharma and M. Singh</td>
</tr>
</tbody>
</table>

**POSTERS**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>DT05</td>
<td>Undergraduate teaching delivery: a practical solution</td>
<td>G. Hale and G. Wylie</td>
</tr>
<tr>
<td>DT06</td>
<td>Dermatology teaching to general practitioner trainees: an unmet need</td>
<td>E. Natafji, A.P. Panthagani and D.A. Mckay</td>
</tr>
<tr>
<td>DT07</td>
<td>Experiences of postgraduate dermatology higher specialist training: a survey of U.K. trainees</td>
<td>E. McNulty-Brown and Z. Venables</td>
</tr>
</tbody>
</table>

The poster viewing session will take place during the lunch break on Tuesday 5th July

**NOTES**
Plenary Session

Date: Tuesday 5th July
Time: 15:00-17:00
Room: Hall 1
Chairs: Dr David Eedy & Dr Nick Levell

PROGRAMME

15:00 – 15:30
Keynote Lecture - Introduced by Dr David Eedy
The interpretation of sentinel lymph nodes for melanoma
Professor Martin Cook (Guildford, UK)

There is much discussion of which patients with melanoma should be offered a sentinel lymph node biopsy and what is the significance of the result. Less consideration has been given to the procedures involved in the pathological assessment of sentinel lymph nodes. It is still not clear how exhaustive the examination should be with recommendations ranging from a few sections to a structured step wise examination of much more or all of the node. Recording of metastases in the node may be simply noted as present or absent but at the other extreme includes assessment based on automated tumour volume calculations.

The pathological assessment can vary at the stage of dissection, sectioning, staining protocol as well as microscopy. False positives should also be considered since “benign metastases” are not infrequent. At this stage of our understanding of the merits of sentinel lymph node biopsy for melanoma, the pathological assessment should result in more than a simple positive/negative answer.

15:30 – 15:50
Invited Lecture
The skin and gut microbiome in atopic eczema
Dr Carsten Flohr (London)

15:50 – 16:10
Invited Lecture
The Dual Allergen Exposure Hypothesis: transcutaneous sensitisation versus oral tolerance induction
Dr Helen Brough (London)

16:10 – 16:30
Invited Lecture
A newly discovered innate lymphocyte population in the skin
Professor Graham Ogg (Oxford)

16:30 – 17:00
Keynote Lecture – Introduced by Dr David Eedy
Radiotherapy and skin cancer: The never ending battle and the perspective of an Aussie Radiation Oncologist
Professor Michael Veness (Sydney, Australia)

Australians experience the highest rate of skin cancer in the world with the rate increasing on a global basis. As such skin cancer patients represent a huge and increasing burden on many health systems. An expanding range of modalities and disciplines are involved in managing these patients which includes radiotherapy. Definitive radiotherapy is an efficacious alternative in select patients and an adjuvant treatment in many, often high-risk, patients. Although the majority of skin cancer patients may never require referral to a radiation oncologist clinicians managing these patients should at least have an understanding of the role of radiotherapy.

NOTES
**Wednesday 6 July Overview**

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION DETAIL</th>
<th>ROOM</th>
<th>INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 – 08:30</td>
<td>Christian Medical Fellowship Breakfast</td>
<td>Executive 2</td>
<td>Page 34</td>
</tr>
<tr>
<td>07:45 – 08:30</td>
<td>LEO Pharma Sponsored Symposium</td>
<td>Hall 10</td>
<td>Page 35</td>
</tr>
<tr>
<td>07:45 – 08:30</td>
<td>Celgene Sponsored Symposium</td>
<td>Hall 9</td>
<td>Page 35</td>
</tr>
<tr>
<td>08:30 – 12:25</td>
<td>Plenary session - Medical Dermatology</td>
<td>Hall 1</td>
<td>Page 36</td>
</tr>
<tr>
<td>08:45 – 12:45</td>
<td>British Cosmetic Dermatology Group</td>
<td>Hall 8a</td>
<td>Page 37</td>
</tr>
<tr>
<td>10:30 – 10:50</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>10:30 – 10:50</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td>International Psoriasis Council – Meet the expert</td>
<td>Hall 5</td>
<td>Page 38</td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td>Improving Patient Wellbeing and Outcomes</td>
<td>Hall 9</td>
<td>Page 39</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>La Roche-Posay Sponsored Symposium</td>
<td>Hall 9</td>
<td>Page 40</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Lilly Sponsored Symposium</td>
<td>Hall 10</td>
<td>Page 41</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Sanofi Genzyme Sponsored Symposium</td>
<td>Hall 5</td>
<td>Page 42</td>
</tr>
<tr>
<td>14:00 – 15:15</td>
<td>Scientific Session – submitted papers</td>
<td>Hall 1</td>
<td>Page 43</td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>British Society for Investigative Dermatology - open to all</td>
<td>Hall 8a</td>
<td>Page 44</td>
</tr>
<tr>
<td>14:30 – 17:25</td>
<td>Psychodermatology</td>
<td>Hall 5</td>
<td>Page 45-46</td>
</tr>
<tr>
<td>14:30 – 15:45</td>
<td>Historical Symposium</td>
<td>Hall 9</td>
<td>Page 47-48</td>
</tr>
<tr>
<td>14:30 – 17:00</td>
<td>British Teledermatology Society</td>
<td>Hall 10</td>
<td>Page 49</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>15:30 – 15:50</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>16:00 – 16:15</td>
<td>Presidents Address – Dr Nick Levell</td>
<td>Hall 1</td>
<td>Page 50</td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td>Keynote Lecture: Professor Kieron Leslie</td>
<td>Hall 1</td>
<td>Page 50</td>
</tr>
<tr>
<td>16:45 – 17:45</td>
<td>Plenary Session</td>
<td>Hall 1</td>
<td>Page 50</td>
</tr>
<tr>
<td>17:45 – 18:15</td>
<td>Keynote Lecture: Professor Donald Leung</td>
<td>Hall 1</td>
<td>Page 50</td>
</tr>
<tr>
<td>18:15 – 19:00</td>
<td>Sobi Sponsored Symposium</td>
<td>Hall 9</td>
<td>Page 51</td>
</tr>
<tr>
<td>18:15 – 19:00</td>
<td>Bristol Myers Squibb Sponsored Symposium</td>
<td>Hall 10</td>
<td>Page 52</td>
</tr>
</tbody>
</table>
Sponsored Symposium: LEO Pharma

Date:            Wednesday 6th July
Time:           07:45 – 08:30
Room:          Hall 10
Chair:           Professor Chris Griffiths

Redefining Expectations of Topical Treatment in Psoriasis

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45 - 07:50</td>
<td>Welcome and Introduction</td>
<td>Professor Chris Griffiths (Manchester)</td>
</tr>
<tr>
<td>07:50 - 08:00</td>
<td>The current topicals – Can patients expect more?</td>
<td>Dr Vicky Jolliffe (London)</td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>Raising the bar in topical treatment – The clinical data</td>
<td>Professor Chris Griffiths (Manchester)</td>
</tr>
<tr>
<td>08:15 - 08:25</td>
<td>Beyond the clinical data – Who can benefit?</td>
<td>Professor Rino Cerio (London)</td>
</tr>
<tr>
<td>08:25 - 08:30</td>
<td>Audience Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Sponsored Symposium: Celgene

Date:       Wednesday 6th July
Time:       07:45 – 08:30
Room:       Hall 9
Chair:      Professor Frank Nestle

Redefining the treatment of psoriasis in the UK: real world experience

<table>
<thead>
<tr>
<th>TIME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45</td>
<td><strong>Opportunities for targeted pathways in psoriasis</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Frank Nestle (London)</td>
</tr>
<tr>
<td>07:55</td>
<td><strong>What do new treatments mean for psoriasis pathways?</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Richard Warren (Manchester)</td>
</tr>
<tr>
<td>08:10</td>
<td><strong>Real world experience with Otezla; the story so far</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Alison Bedlow (Warwick)</td>
</tr>
<tr>
<td>08:25</td>
<td><strong>Audience Q &amp; A</strong></td>
</tr>
</tbody>
</table>

NOTES

........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
**PROGRAMME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 – 09:10</td>
<td>MD01</td>
<td>Pathophysiology and therapy of rosacea: new developments</td>
<td>Prof Martin Steinhoff (Dublin, Ireland)</td>
</tr>
<tr>
<td>09:25 – 09:40</td>
<td>O03</td>
<td>The primary care management of hidradenitis suppurativa (HS) in the UK: an evaluation of patient pathways and healthcare resource use using The Health Improvement Network (THIN) database</td>
<td>A. Bewley, B. Malcolm and Prashanti Shah</td>
</tr>
<tr>
<td>09:40 – 10:05</td>
<td>MD02</td>
<td>What's New in Acne</td>
<td>Dr Alison Layton (Harrogate)</td>
</tr>
<tr>
<td>10:05 – 10:50</td>
<td>Break</td>
<td></td>
<td>Exhibition Hall</td>
</tr>
<tr>
<td>10:50 – 11:05</td>
<td>O04</td>
<td>The Patient-Oriented Eczema Measure Of Eczema Severity In Young Children: Responsiveness And Minimal Clinically Important Difference</td>
<td>D.M. Gaunt, C. Metcalfe and M. Ridd</td>
</tr>
<tr>
<td>11:05 – 11:30</td>
<td>MD03</td>
<td>Oral mucosal matters</td>
<td>Dr Jane Setterfield (London)</td>
</tr>
<tr>
<td>12:00 – 12:25</td>
<td>MD04</td>
<td>Answers to alopecia</td>
<td>Dr Matthew Harries (Manchester)</td>
</tr>
</tbody>
</table>
### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 – 08:50</td>
<td>Introduction – Dr Sean Lanigan (Birmingham)</td>
</tr>
</tbody>
</table>
| 08:50 – 09:10 | BCGL1 How to start cosmetic rejuvenation procedures.  
                Dr Nisith Sheth (London)                                      |
| 09:10 – 09:30 | BCGL2 Ageing of the face  
                Dr Richard Barlow (London)                                    |
| 09:30 – 09:40 | BC01 Liquid topical acrylate skin adhesive for treatment of a bleeding infantile haemangioma  
                R. Urwin and R. Sheehan-Dare                                     |
| 09:40 – 09:50 | BC02 Carbon dioxide laser ablation of dermatosis papulosa nigra: high patient satisfaction and few complications in patients with pigmented skin  
                F.R. Ali, J.E. Ferguson and Vishal Madan                           |
| 09:50 – 10:10 | BCGL3 Thread lifting for facial rejuvenation  
                Dr Bav Shergill (Brighton)                                      |
| 10:10 – 11:00 | Break Exhibition Hall                                                 |
| 11:00 – 11:10 | BC03 Granuloma annulare-like response to mesotherapy  
                R. Nalluri and T. Griffiths                                       |
| 11:10 – 11:20 | BC04 A study of combined use of microneedling and platelet-rich plasma on acne scars  
                S. Vongumalli and M.L. Midde                                      |
| 11:20 – 11:40 | BCGL4 Side Effects of Aesthetic procedures  
                Dr Sweta Rai (London)                                             |
| 11:40 – 12:00 | BCGL5 Neocollagenesis with injectables  
                Dr Nick Lowe (London)                                            |
| 12:00 – 12:15 | Questions and Discussion                                             |
| 12:15 – 12:45 | AGM                                                                  |

### POSTERS

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
</tr>
</thead>
</table>
| BG05   | Topical monobenzylether of hydroquinone for depigmentation of extensive vitiligo: a retrospective cohort study of 53 cases  
                W. Alwan, E. Sern-Ting Tan and R. Sarkany                          |
| BG06   | Erbium:yttrium aluminium garnet laser treatment of multiple facial trichoepitheliomata in a patient with type VI skin  
                R. Urwin and R. Sheehan-Dare                                      |
| BG07   | Spiny keratoderma of the palms treated with erbium:yttrium aluminium garnet ablation  
                R. Urwin and R. Sheehan-Dare                                      |
| BG08   | Delayed granulomatous reaction to dermal fillers treated with intrallesional triamcinolone and oral minocycline  
                C. Duhovic and E. Duarte-Williamson                                |

The poster viewing session will take place during the morning coffee break on Wednesday 6th July.
## International Psoriasis Council – Meet the expert

**Date:** Wednesday 6th July  
**Time:** 11:00 -12:30  
**Room:** Hall 5  
**Chair:** Professor Chris Griffiths

### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:05</td>
<td>Welcome and Overview</td>
<td>Professor Chris Griffiths (Manchester)</td>
</tr>
<tr>
<td>11:05 – 11:25</td>
<td>Case: Expect the Unexpected</td>
<td>Dr Richard Warren (Manchester)</td>
</tr>
<tr>
<td>11:25 – 11:45</td>
<td>Case: Poor Response to Multiple Biologics</td>
<td>Professor Catherine Smith (London)</td>
</tr>
<tr>
<td>11:45 – 12:05</td>
<td>Case: Serious Infection Whilst On Biological Therapy: Acute and Subsequent Management</td>
<td>Professor Nick Reynolds (Newcastle)</td>
</tr>
<tr>
<td>12:05 – 12:25</td>
<td>Case: Adherence Is the Key to Successful Outcomes - Engagement is the Key to Adherence</td>
<td>Dr Chris Bundy (Manchester)</td>
</tr>
<tr>
<td>12:25 – 12:30</td>
<td>Closing Comments</td>
<td>Professor Chris Griffiths (Manchester)</td>
</tr>
</tbody>
</table>

*Discussion amongst panel and audience will follow each case presentation*

### NOTES
## Improving Patient Wellbeing and Outcomes

**Date:** Wednesday 6th July  
**Time:** 11:00-12:30  
**Room:** Hall 9  
**Chairs:** Professor Celia Moss & Diana Perry

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
</table>
| 11:00 – 11:05 | **Welcome and Introduction**  
Prof Celia Moss |
| 11:05 – 11:35 | **Information**  
*The doctor-PSG relationship - how to pull together*  
Dr Veronica Kinsler  
*Dermatologist*  
*I'm still me*  
Elizabeth Allen - British Association of Skin Camouflage  
*Patient*  
*Why contact a Patient Support Group?*  
Mandy Aldwin - Ichthyosis Support Group  
*PSG rep* |
| 11:35 – 12:05 | **Impact**  
*More Than Skin Deep*  
Dr Susannah Baron  
*Dermatologist*  
*Negative and positive influences of social media - Dr Google - validity of the information online!*  
Diana Perry - Ectodermal Dysplasia Society  
*PSG rep*  
*A personal experience of alopecia and the role of the PSG in improving a patient's well-being*  
Amy Johnson – Alopecia UK  
*Patient* |
| 12:05 – 12:25 | **Interaction**  
Q & A and Audience participation |
| 12:25 – 12:30 | **Closing Remarks**  
From Session Chairs |

## NOTES

---

---

---

---

---

---

---

---

---
Sponsored Symposium: La Roche-Posay

**Date:** Wednesday 6th July
**Time:** 13:00 – 14:00
**Room:** Hall 9
**Chair:** Dr Robert Sarkany

**UV: Science, psychology and society**

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:15</td>
<td>Welcome and introduction&lt;br&gt;Dr Robert Sarkany (London)</td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>Mechanisms of photocarcinogenesis&lt;br&gt;Dr Hiva Fassihi (London)</td>
</tr>
<tr>
<td>13:30 – 13:55</td>
<td>Photoprotection: What should we be telling our patients?&lt;br&gt;Dr Robert Sarkany (London)</td>
</tr>
<tr>
<td>13:55 – 14:00</td>
<td>A social history of UV light&lt;br&gt;Dr Tanya Woloshyn (Coventry)</td>
</tr>
<tr>
<td></td>
<td>Discussion, questions and answers&lt;br&gt;Panel of speakers, facilitated by Dr Robert Sarkany (London)</td>
</tr>
</tbody>
</table>

**LA ROCHE-POSAY ANTHELIOS XL**

Very high sun protection, specifically designed for sensitive skin.

Over the last 30 years, La Roche-Posay has developed unique expertise in sun protection and established its pioneering Anthelios range offering very high UVA/UVB protection, as the «go-to» sun protection range for sensitive skin. Anthelios XL Cream SPF50+ has been reformulated to contain Baicalin, an anti-oxidant.
Sponsored Symposium: Lilly

Date:       Wednesday 6th July
Time:       13:00 – 14:00
Room:       Hall 10
Chair:      Dr Joyce Leman

Uncovering new paradigms in the treatment of moderate to severe psoriasis

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:10</td>
<td>Chair’s introduction&lt;br&gt;Dr Joyce Leman (Glasgow)</td>
</tr>
<tr>
<td>13:10 – 13:30</td>
<td>New clinical approaches towards improving patient outcomes: rationale for IL-17A targeting&lt;br&gt;Professor Frank Nestle (London)</td>
</tr>
<tr>
<td>13:30 – 13:50</td>
<td>UNCOVER clinical development programme: efficacy and safety of ixekizumab in patients with moderate to severe psoriasis&lt;br&gt;Professor Chris Griffiths (Manchester)</td>
</tr>
<tr>
<td>13:50 – 14:00</td>
<td>Questions from the audience</td>
</tr>
</tbody>
</table>

NOTES
Sponsored Symposium: Sanofi Genzyme

Date: Wednesday 6th July  
Time: 13:00 – 14:00  
Room: Hall 5  
Chair: Professor Michael Cork

New Frontiers and Treatment Advances for Atopic dermatitis

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:20</td>
<td>Epidemiology, Diagnosis and Assessment of Atopic Dermatitis</td>
</tr>
<tr>
<td></td>
<td>Professor Thomas Bieber (Bonn, Germany)</td>
</tr>
<tr>
<td>13:20 – 13:40</td>
<td>Scientific advances in the understanding of Atopic Dermatitis and Current Options for Systemic Therapy</td>
</tr>
<tr>
<td></td>
<td>Professor Alan Irvine (Dublin)</td>
</tr>
<tr>
<td>13:40 – 14:00</td>
<td>Emerging therapies in the treatment of Atopic Dermatitis</td>
</tr>
<tr>
<td></td>
<td>Professor Michael Cork (Sheffield)</td>
</tr>
</tbody>
</table>

NOTES
Scientific Session – submitted papers

Date:       Wednesday 6th July
Time:       14:00-15:15
Room:       Hall 1
Chairs:     Dr Richard Groves & Dr Anshoo Sahota

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:15</td>
<td>BMJ Dermatology Team of the Year: Holistic care for skin disease</td>
</tr>
<tr>
<td></td>
<td>C. Smith, S. Langan and K. Jackson</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>O07 Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis</td>
</tr>
<tr>
<td></td>
<td>M. Plotnick, K. Li, C. Huang, Y. Wasfi, B. Randazzo, S. Li, P. Szapary, K. Campbell and C. Brodmerkel</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>O08 Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis</td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>O09 British Association of Dermatologists (BAD) national audit on non-melanoma skin cancer excision 2014</td>
</tr>
<tr>
<td></td>
<td>D. Keith, D. de Berker, A. Bray, S. Cheung, A. Brain, M.F. Mohd Mustapa</td>
</tr>
<tr>
<td>15:00 – 15:15</td>
<td>O10 Chemoprevention of cutaneous squamous cell carcinoma with acitretin in renal transplant recipients: a case-controlled analysis</td>
</tr>
<tr>
<td></td>
<td>R. Anand, A. Cronin, S. Frame, R. Hung, K. Bramham and M. Wain</td>
</tr>
</tbody>
</table>
**British Society for Investigative Dermatology – open to all**

**Date:** Wednesday 6th July  
**Time:** 14:00 - 15:30  
**Room:** Hall 8a  
**Chairs:** Dr Michael Ardern-Jones & Dr Helen Young

**PROGRAMME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:10</td>
<td>BS01</td>
<td>Best early Investigator Prize</td>
<td>F. Kenny, A. Kao, A. Barber, E. O’Toole, J. Connelly</td>
</tr>
<tr>
<td>14:10 – 14:40</td>
<td>BSGL1</td>
<td>Recent advances in our understanding of how the skin barrier regulates cutaneous inflammation</td>
<td>Professor Graham Ogg (Oxford)</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>BSGL2</td>
<td>Novel concepts in skin tumour growth</td>
<td>Dr Neil Rajan (Newcastle)</td>
</tr>
</tbody>
</table>

**NOTES**
**Psychodermatology UK**

**Date:** Wednesday 6th July  
**Time:** 14:30 – 17:25  
**Room:** Hall 5  
**Chairs:** Dr Andrew Affleck & Dr Susannah Baron

### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 – 15:00</td>
<td>PSGL1</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mindfulness meditation and psoriasis</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Professor Brian Kirby (Dublin, Ireland)</em></td>
</tr>
<tr>
<td>15:00 – 15:10</td>
<td>PS01</td>
<td>Evaluation of the IMPACT study practitioner training intervention: using motivational interviewing to optimize self-management in psoriasis</td>
</tr>
<tr>
<td>15:10 – 15:20</td>
<td>PS02</td>
<td>Obesity, low mood, negative beliefs about illness and severity of psoriasis are linked to dysfunctional eating patterns</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Bundy, C. Pearce, J. Sergent and C.E.M. Griffiths</td>
</tr>
<tr>
<td>15:20 – 15:30</td>
<td>PS03</td>
<td>A survey of sleep disturbance in psoriasis</td>
</tr>
<tr>
<td>15:30 – 16:15</td>
<td>Break</td>
<td>Exhibition Hall</td>
</tr>
<tr>
<td>16:15 – 16:25</td>
<td>PS04</td>
<td>Acceptance and resilience in chronic skin disease: a pilot observational study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Affleck and P. Bell</td>
</tr>
<tr>
<td>16:25 – 16:35</td>
<td>PS05</td>
<td>‘Not only skin deep’: an evaluation of a pilot psychodermatology service in an Irish hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L. Murphy, E. Moran, J. Wilson O’Raghallaigh, L. Power, M. Cannon and M. O’Kane</td>
</tr>
<tr>
<td>16:35 – 16:45</td>
<td>PS06</td>
<td>Psychological distress in patients with hidradenitis suppurativa</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Kirhti, R. Hellen, R. O’Connor, M. Connolly and A.-M. Tobin</td>
</tr>
<tr>
<td>16:45 – 16:55</td>
<td>PS07</td>
<td>The combined approach to treating atopic dermatitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. George, M. Culhane, J. Hutton, M. Turner, C. Bridgett and S. Walsh</td>
</tr>
<tr>
<td>16:55 – 17:05</td>
<td>PS08</td>
<td>Mindfulness for eczema: a review of a small pilot group</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L. Hankinson, D. O’Driscoll and H. Malhomme De La Roche</td>
</tr>
<tr>
<td>17:05 – 17:15</td>
<td>PS09</td>
<td>A case series of acne excoriée: are we scratching the surface?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H. Cordey and A. Affleck</td>
</tr>
<tr>
<td>17:15 – 17:25</td>
<td>PS10</td>
<td>What’s that smell?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G. Fremlin, K. Martin and J.M.R. Goulding</td>
</tr>
</tbody>
</table>

### POSTERS

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS11</td>
<td>Colour your judgement purple to avoid missing a rare diagnosis</td>
</tr>
<tr>
<td></td>
<td>A. Wernham, G. Fremlin and S. Orpin</td>
</tr>
<tr>
<td>PS12</td>
<td>Development and evaluation of the IMPACT programme patient resources to increase understanding of psoriasis and its management: a mixed-methods feasibility study</td>
</tr>
<tr>
<td>PS13</td>
<td>‘Patient’, ‘client’ or ‘service user’? A survey of preferred terms of address among those attending dermatology clinics.</td>
</tr>
<tr>
<td></td>
<td>M. Anyasodor and A. Bewley</td>
</tr>
<tr>
<td>PS14</td>
<td>Utility of patient-reported outcome measures in nonmelanoma skin cancers</td>
</tr>
<tr>
<td></td>
<td>G. Wall, E. Gibbons, T. Mackenzie, W. Perkins, J. Reed, R. Turner and R. Matin</td>
</tr>
<tr>
<td>PS15</td>
<td>‘The crucified patient’: dermatitis artefacta presenting with cruciform ulceration and deafness</td>
</tr>
<tr>
<td></td>
<td>L. Roche, M. Lynch, K. Ahmad, C. Hackett, S. Ryan, J. Devlin and B. Ramsay</td>
</tr>
<tr>
<td>PS16</td>
<td>A rare case of delusional infestations by proxy in two adults</td>
</tr>
<tr>
<td></td>
<td>S. Shinhmar, R. Taylor and A. Bewley</td>
</tr>
<tr>
<td>PS17</td>
<td>Occupational nostalgia paraesthetica: the curse of being tall</td>
</tr>
<tr>
<td></td>
<td>P. Falkner and A. Ahmed Mughal</td>
</tr>
<tr>
<td>PS18</td>
<td>Histological findings in dermatitis artefacta: a case series review</td>
</tr>
<tr>
<td></td>
<td>D. O Callaghan, D. Markiewicz, E. Blakeway, S. Shinhmar and A. Bewley</td>
</tr>
<tr>
<td>PS19</td>
<td>A psychodermatology patient with a multitude of psychological comorbidities</td>
</tr>
<tr>
<td></td>
<td>T. Taney and A. Bewley</td>
</tr>
</tbody>
</table>
More rapid improvement in quality of life with fixed combination calcipotriene plus betamethasone dipropionate aerosol foam vs. topical suspension (PSO-ABLE study in patients with psoriasis vulgaris)

C. Paul, L. Stein Gold, F. Cambazard, R.E. Kalb, D. Lowson, A. Holmen Møller and C.E.M. Griffiths

The poster viewing session will take place during the afternoon coffee break on Wednesday 6th July
Historical Symposium

Date: Wednesday 6th July
Time: 14:30 – 15:45
Room: Hall 9
Chair: Dr Frances Humphreys

PROGRAMME

14:30 – 14:42 H01 The medicalization of workhouses in the 18th and 19th centuries and the development of facilities for paupers with venereal disease and ‘the itch’
D.J. Gawkrodger

14:42 – 14:54 H02 Soliman’s Water to Kligman’s Formula: skin bleaching through the ages
D. Tabor and M. Tidman

14:54 – 15:06 H03 ‘The largest mass poisoning of a population in history’
M. Cheesbrough

15:06 – 15:18 H04 The ultimate misdiagnosis: witches’ marks and dermatology in the 17th century
L. Nemazee, R.B. Warren and A.C. Foulkes

15:18 – 15:45 HGL Guest Lecture
Lesions, landscapes and locales: the topography of skin in the nineteenth century
Professor Jonathan Reinarz (Birmingham)

The study of skin is among the most visual of medical specialties, and skin atlases are among the most visually compelling medical publications. The latter date from the emergence of nineteenth-century specialist skin hospitals in Europe. In this talk Professor Jonathan Reinarz, Director of the History of Medicine Unit, will explore the visual representation of skin diseases, drawing from a number of ground breaking texts from the Cadbury Research Library at the University of Birmingham. Besides tracing the development of this medical speciality over the nineteenth century through images from works by Robert Willan, Jean-Louis Alibert, Thomas Bateman, Pierre Rayer and Henry Radcliffe Crocke, among others, he will end by describing the emergence of specialist care for skin diseases in late-Victorian Birmingham.

POSTERS

H05 The history of Merkel cell carcinoma
R.S. Rashid and A. Ilchyshyn

H06 The King’s Evil
S. Winters and P.D. Yesudian

H07 Henri Gougerot: the arbiter of French dermatology
N. Nataf, S. Ball and A. Panthagani

H08 Touching on the life and legacy of Friedrich Sigmund Merkel (1845–1919)
D. Tabor and M. Tidman

H09 Father Damien: the saint of lepers and pioneer of leprosy treatment
K.E. Davies and P.D. Yesudian

H10 ‘Il sorriso di un bambino guarito ha un valore inestimabile’. The life and work of Ferdinando Gianotti (1920–1984), a pioneer in paediatric dermatology
H. Saigal and S. Orpin

H11 Skin disease and the emotion disgust: an historical perspective
S. Moschogianis, S. McKie, R. Elliott and E. Kleyn

H12 The tan: a golden or aged concept?
R.M. Fisher and S.I. Goolamali

H13 Robert Cranston Low: artist and scientist
R. Jones and J.A.A. Hunter

H14 2016: a skin odyssey
J. Clowry, E.N. Dhonncha and S. Field

H15 ‘But what is the black spot captain?’ I asked. ‘That’s a summons mate’
N. Dinani, E. McNulty-Brown and P. Coburn

H16 Peeling back the years: a history of chemical peels
O. Orekoya, B. Oremule and T. Hanna

H17 The ‘Reading’ bacillus: a serendipitous discovery during the First World War
R.M. Fisher, H. Malhomme and T. Smith
The poster viewing session will take place between 12:30 and 13:00 on Wednesday 6th July

Please remember to go and visit the BAD stand located in the reception area to see our historical display.
### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 – 14:45</td>
<td>Welcome Introduction</td>
</tr>
<tr>
<td></td>
<td>Dr Saul Halpern</td>
</tr>
<tr>
<td></td>
<td>Teledermatology 2016</td>
</tr>
<tr>
<td>14:45 – 14:57</td>
<td>BT01 Picture this: a local acute teledermatology service</td>
</tr>
<tr>
<td></td>
<td>A. Lock, S. Ziaji, J. Gale, A. Gulati, S. Chinthapalli, S. Nasir, R. Mokbel, M. Sommerlad and R. Goiriz</td>
</tr>
<tr>
<td>14:57 – 15:09</td>
<td>BT02 A study evaluating the use of smartphones to photograph patients by U.K. dermatologists</td>
</tr>
<tr>
<td></td>
<td>H. Alexander and S. Halpern</td>
</tr>
<tr>
<td>15:09 – 15:21</td>
<td>BT03 Teledermatology to triage 2-week-wait referrals: a ‘real-world’ pilot study using an iPhone 5S</td>
</tr>
<tr>
<td></td>
<td>T. Nelson, I. Pearson and J. Hickey</td>
</tr>
<tr>
<td></td>
<td>C. Charman and Y. Al-Nuaimi</td>
</tr>
<tr>
<td>15:33 – 15:45</td>
<td>BT05 An innovative role of the teledermatology service: tracking an outbreak of atypical hand, foot and mouth disease in the community</td>
</tr>
<tr>
<td></td>
<td>A. Lloyd-Lavery, M. Lin, R. Turner and T. McPherson</td>
</tr>
<tr>
<td>15:45 – 16:00</td>
<td>Break Exhibition Hall</td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td>AGM</td>
</tr>
</tbody>
</table>

**6th World Congress of Teledermatology**

**London**

**14-15 Oct 2016**

[www.teledermatology2016.com](http://www.teledermatology2016.com)
**Plenary Session**

**Date:** Wednesday 6th July  
**Time:** 16:00-18:15  
**Room:** Hall 1  
**Chairs:** Dr Nick Levell & Dr Ruth Murphy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:00 – 16:15 | Presidents Address  
Dr Nick Levell |
| 16:15 – 16:45 | Keynote Lecture - Introduced by Dr Nick Levell  
*Hot Ice, me thinks: all you need to know about autoinflammation as explained by William Shakespeare*  
Professor Kieron Leslie (San Francisco, USA)  
Autoinflammation is characterised by aberrant regulation of the innate immune system and often manifests as periodic fevers and systemic inflammation involving multiple organs, including the skin. Mutations leading to abnormal behaviour or activity of the interleukin 1 beta (IL-1ß)-processing inflammasome complex have been found in several rare autoinflammatory syndromes, for which anticytokine therapy such as IL-1 or tumour necrosis factor-alfa inhibition may be effective. It is becoming clear that features of autoinflammation also affect common dermatoses, some of which were previously thought to be solely autoimmune in origin (e.g., vitiligo, systemic lupus erythematosus). Recognizing the pathogenetic role of autoinflammation can open up new avenues for the targeted treatment of complex, inflammatory dermatoses. 2017 is the 400th anniversary of William Shakespeare’s death; analysis of his writings suggest that he may have predicted autoinflammatory disorders 382 years before modern medical science described them. |
| 16:45 – 17:05 | IL4 Invited Lecture  
*Itch: Molecular mechanisms and new therapies*  
Professor Martin Steinhoff (Dublin, Ireland) |
| 17:05 – 17:25 | IL5 Invited Lecture  
*The Next Revolution: Computational Biology and the Skin*  
Dr Stephen Smith (Cambridge) |
| 17:25 – 17:45 | IL6 Invited Lecture  
*Drug Reactions*  
Dr Michael Ardern-Jones (Southampton) |
| 17:45 – 18:15 | Keynote Lecture – Introduced by Dr Ruth Murphy  
*Mechanisms of Infection in Atopic Dermatitis*  
Professor Donald Leung (Denver, USA)  
Atopic Dermatitis is commonly associated with bacterial and viral skin infections. During the past few years, there has been substantial progress in our understanding of how epithelial barrier dysfunction, as well as aberrant innate and adaptive immune responses contribute to the increased propensity of patients with atopic dermatitis to infection. This lecture will review mechanisms of infection in atopic dermatitis and how these mechanisms may form the basis for new treatment approaches to reduce skin infections. |
Sponsored Symposium: Sobi

Date: Wednesday 6th July
Time: 18:15 – 19:00
Room: Hall 9
Chair: Dr Tim Clayton

CAPS: Auto-inflammatory syndromes – a rash diagnosis

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:15 – 18:20</td>
<td>Welcome and Introduction</td>
<td>Dr Tim Clayton (Manchester)</td>
</tr>
<tr>
<td>18:20 – 18:30</td>
<td>Working with your Paediatric Rheumatologist</td>
<td>Dr Tim Clayton (Manchester)</td>
</tr>
<tr>
<td>18:30 – 18:50</td>
<td>CAPS: Auto-inflammatory syndromes – a rash diagnosis</td>
<td>Dr Phil Riley (Manchester)</td>
</tr>
<tr>
<td>18:50 – 19:00</td>
<td>Summary, Questions and Close</td>
<td></td>
</tr>
</tbody>
</table>

NOTES
The Power of Combination in Melanoma

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:15 – 18:20</td>
<td>Introduction</td>
<td>Dr Louise Fearfield (London)</td>
</tr>
<tr>
<td>18:20 – 18:35</td>
<td>Immuno-Oncology: A Review of the Basics</td>
<td>Dr Sergio Quezada (London)</td>
</tr>
<tr>
<td>18:35 – 18:50</td>
<td>Combination Treatments: The Future of Front-Line Therapy in Metastatic Melanoma</td>
<td>Professor Jeff Evans (Glasgow)</td>
</tr>
<tr>
<td>18:55 – 19:00</td>
<td>Case Study</td>
<td>Dr Louise Fearfield (London)</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A</td>
<td>All faculty</td>
</tr>
</tbody>
</table>

During the session there will be the opportunity for discussion and questions from the audience.

This symposium is organised and funded by Bristol-Myers Squibb.
<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION DETAIL</th>
<th>ROOM</th>
<th>INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 10:05</td>
<td>Plenary session – International Dermatology</td>
<td>Hall 1</td>
<td>Page 54</td>
</tr>
<tr>
<td>08:30 – 12:02</td>
<td>British Society for Paediatric Dermatology</td>
<td>Hall 5</td>
<td>Page 55-56</td>
</tr>
<tr>
<td>08:30 – 12:15</td>
<td>British Photodermatology Group</td>
<td>Hall 9</td>
<td>Page 57-58</td>
</tr>
<tr>
<td>08:30 – 10:00</td>
<td>UK Trend</td>
<td>Hall 10</td>
<td>Page 59</td>
</tr>
<tr>
<td>10:15 – 10:45</td>
<td>Hot Topics</td>
<td>Exhibition</td>
<td>Page 67</td>
</tr>
<tr>
<td>10:15 – 10:35</td>
<td>Poster Presentations</td>
<td>Hall 4</td>
<td>Page 69</td>
</tr>
<tr>
<td>10:45 – 12:15</td>
<td>Registrars Symposium</td>
<td>Hall 1</td>
<td>Page 60</td>
</tr>
<tr>
<td>10:45 – 12:15</td>
<td>British Hair &amp; Nail Society</td>
<td>Hall 10</td>
<td>Page 61</td>
</tr>
<tr>
<td>12:30 – 13:15</td>
<td>Pharma Presentations</td>
<td>Exhibition Hall</td>
<td>Page 67</td>
</tr>
<tr>
<td>13:15 – 17:30</td>
<td>BADGEM</td>
<td>Hall 5</td>
<td>Page 62-63</td>
</tr>
<tr>
<td>13:15 – 13:45</td>
<td>Keynote Lecture: Dr Chetan Mukhtyar</td>
<td>Hall 1</td>
<td>Page 64</td>
</tr>
<tr>
<td>13:45 – 14:25</td>
<td>Plenary Session</td>
<td>Hall 1</td>
<td>Page 64</td>
</tr>
<tr>
<td>14:25 – 15:10</td>
<td>Arthur Rook Oration: Professor Irwin McLean</td>
<td>Hall 1</td>
<td>Page 65</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Focus Session: Dermatomyositis: clinical phenotypes and associated autoantibodies</td>
<td>Hall 6</td>
<td>Page 66</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Focus Session: Management Controversies in SJS/TEN</td>
<td>Hall 10</td>
<td>Page 66</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Focus Session: Urticaria Past, Present and Future</td>
<td>Hall 9</td>
<td>Page 66</td>
</tr>
<tr>
<td>16:00 – 17:30</td>
<td>CPD update</td>
<td>Hall 1</td>
<td>Page 65</td>
</tr>
</tbody>
</table>
International Dermatology Session

Date: Thursday 7th July
Time: 08:30 – 10:05
Room: Hall 1
Chairs: Professor Chris Bunker & Dr Karen Gibbon

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 08:30 – 09:00 | Invited Lecture
HIV Dermatology from California to Kampala (via Birmingham), a global challenge
Professor Kieron Leslie (San Francisco, USA) |
| 09:00 – 09:15 | Clinical and immunological outcomes of treatment with rituximab vs combination of
rituximab and intravenous cyclophosphamid in treatment of refractory pemphigus: a pilot
randomized double blind study
U. Shraddha, S. Dogra, S. Handa, K. Vinay, B. Saikia and N. Joshi |
| 09:15 – 09:30 | Abstract withdrawn |
| 09:30 – 09:50 | Invited Lecture
Gene therapy in Dermatology
Professor Johann Bauer (Salzburg, Austria) |
| 09:50 – 10:05 | Leprosy in Kiribati: understanding the challenges and progress towards elimination
E. Trowbridge, A. Cunanan, S. Chambers, A. Tonganibeia, N. Ioteba and J. Green |

**POSTERS**

| INT01 | Porokeratosis vs. annular/hypertrophic lichen planus: through a dermoscope
P. Saraogi, S. Mishra, S. Mahajan and U. Khopkar |
| INT02 | Developing a severity scale for erythema nodosum leprosum: the ENLIST Erythema
Nodosum Leprosum Severity Scale

*The poster viewing session will take place during the lunchbreak on Thursday 7th July*
# British Society for Paediatric Dermatology

**Date:** Thursday 7th July  
**Time:** 08:30 – 12:02  
**Room:** Hall 5  
**Chairs:** Dr Ruth Murphy & Dr Jemma Mellerio  
Dr Carsten Flohr & Lindsay Shaw

## PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:40 – 08:50</td>
<td>PA02</td>
<td>Intralesional measles, mumps and rubella vaccine for the treatment of multiple and recalcitrant nongenital cutaneous warts in children: a prospective, uncontrolled open-label study</td>
<td>N. Parmar and S. Kuruvila</td>
</tr>
<tr>
<td>08:50 – 09:00</td>
<td>PA03</td>
<td>Morbidity and mortality in U.K. children with recessive dystrophic epidermolysis bullosa: 16-year data from the National U.K. EB Registry</td>
<td>N. Alband, D.S. Kumar, R. Jones, D. James, M. Ogboli, F. Browne, C. Moss, A.E. Martinez and J.E. Mellerio</td>
</tr>
<tr>
<td>09:00 – 09:10</td>
<td>PA04</td>
<td>Familial BAP1 mutation presenting in a child with innocuous-looking skin lesions demonstrating a histologically distinct subtype of an atypical spitzoid tumour, and fatal parangangioma in the father</td>
<td>R.E. Watchorn, E. Calonje and S. Taibjee</td>
</tr>
<tr>
<td>09:10 – 09:20</td>
<td>PA05</td>
<td>Acitretin use in a paediatric cohort: safety and monitoring</td>
<td>A. Cave, A. Khan, A. Martinez, I. Thanapoulou and V. Kinsler</td>
</tr>
<tr>
<td>09:20 – 09:30</td>
<td>PA06</td>
<td>Sustaining a paediatric dermatology service during a workforce crisis: a model of collaborative working</td>
<td>R. Phillips, L. Wells and J.C. Ravenscroft</td>
</tr>
</tbody>
</table>
| 09:30 – 10:00 | PGL1    | Guest Lecture  
The Skin Barrier in Atopic Dermatitis  
Professor Michael Cork (Sheffield, UK) | |
| 10:00 – 10:45 | Break   | Exhibition Hall | |
| 10:45 – 11:30 | PGL2    | Guest Lecture  
Contemporary weaning of the eczematous infant: a paediatric allergist's perspective  
Dr George du Toit (London) | |
| 11:30 – 11:38 | PA07    | Noonan syndrome with multiple lentigines identified by next-generation sequencing | B. McDonald, M. Amieva, D.P. Kelsell, E.A. O'Toole, E. Burkett-Wright, B. Kerr and K. Batta |
| 11:38 – 11:46 | PA08    | Twenty-year review of congenital absence of skin presenting to a paediatric dermatology department | D. Sathishkumar, J. Kainth, C. Moss and M. Ogboli |
| 11:54 – 12:02 | PA10    | Phototherapy for paediatric dermatoses: data from a single-centre retrospective survey | A. Mamtora, B.J. Gambles, A. Lloyd, R.P. Katugampola and M. Kalavaia |

## POSTERS

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA11</td>
<td>Infantile atopic eczema: association with maternal tryptophan metabolite status</td>
<td>S. El-Heis, S. Crozier, S. Robinson, N. Harvey, C. Cooper, H. Inskip and K.M. Godfrey</td>
</tr>
<tr>
<td>PA12</td>
<td>Fibroadipose vascular anomaly: two cases of a newly described disorder</td>
<td>Q. Razali, V. Dvorakova, A. Irvine, G. O’Regan and R. Watson</td>
</tr>
<tr>
<td>PA13</td>
<td>A case on the PIK3CA-related overgrowth spectrum</td>
<td>A. Dubois, M. Splitt and S. Leech</td>
</tr>
<tr>
<td>PA14</td>
<td>A novel mutation in TGM1 causing nonbullous congenital ichthyosiform erythroderma in identical twins</td>
<td>C. Leitch, T. Williams and L. Taylor</td>
</tr>
<tr>
<td>PA15</td>
<td>Childhood psoriasis and body mass index: results from our paediatric dermatology department</td>
<td>M. Noy, L. Kontoza and N. Roberts</td>
</tr>
</tbody>
</table>
| PA16 | Generalized lymphatic anomaly: therapeutic response to long-term low-dose sirolimus  
V. Dvorakova, G. O'Regan, D. Rea and A. Irvine |
| PA17 | Early recognition and detection of juvenile psoriatic arthritis: a call for a standardized approach to screening  
E. Burden-Teh, K. Thomas, S. Rangaraj and R. Murphy |
| PA18 | Langerhans-cell histiocytosis presents as vulval disease in a 16-year-old girl  
E.N. Dhonncha, J. Clowry, B. Hennessy, J. Stratton and S. Field |
| PA19 | The presence of exaggerated mental creases: a useful marker for pseudoxanthoma elasticum in paediatric patients?  
R. Atkar and N. Burrows |
| PA20 | Basal cell carcinomas in paediatric and young adult patients: a series of 34 patients  
N. Stembridge, G. Meligonis, R. Atkar and P. Todd |
| PA21 | Scurvy mimicking Henoch–Schönlein purpura in child with autism  
M.-L. Lovgren, M. Neil and P.E. Beattie |
| PA22 | Infantile generalized pustular psoriasis and its differential diagnosis  
D. Ismail, V. Madhwapathi, J. Yoo, S. Madhogaria, M. Ogboli and G. Stewart |
| PA23 | A case of Aicardi–Goutières syndrome illustrating the clinical heterogeneity of this disorder  
S. Muthiah, C. Goodhead, M. Friswell, S. Natarajan, Y. Crow, M. Abinun and S. Leech |
| PA24 | Langerhans-cell histiocytosis: a rare case of the congenital self-healing reticulohistiocytosis or ‘Hashimoto–Pritzker’ subtype  
K. Warburton and S. Clark |
| PA25 | Rickets re-emerging: a cautionary tale  
N.R. Arujuna and J. Felton |
| PA26 | Generalized telangiectasia macularis eruptiva perstans with atypical restricted diffuse cutaneous mastocytosis in a child  
N.R. Arujuna and J. Felton |
| PA27 | Linear childhood cutaneous lupus erythematosus following Blashko’s lines  
S. Nasir, R. Cerio, S. Dhoat and D. Paige |
| PA28 | Case report of identical twins with Langerhans-cell histiocytosis  
R. Atkar, C. Fleming and N. Burrows |
| PA29 | Occult bone pathology in McCune–Albright syndrome  
E. Carras, C. Moss, V. Sukumar and P.N. Woo |
| PA30 | Scoping the evidence of the epidemiology of childhood psoriasis  
E. Burden-Teh, K. Thomas, S. Ratib, D. Grindlay, E. Adaji and R. Murphy |
| PA31 | It's not always that simplex  
G. Fremlin, S. Irani and A. Loffeld |
| PA32 | Topical tetracyclines in the paediatric population: are they safe? A survey of British Association of Dermatologists members  
B. McDonald and B. DeSilva |
| PA33 | Pigmented, petechial and purpuric dermatosis of infancy as postinfectious hypersensitive immunological manifestation: case report and review of the literature  
J. Thiele and V. Elangasinghe |
| PA34 | Chronic cutaneous ulcer secondary to bacille Calmette–Guérin-osis caused by likely underlying Mendelian susceptibility to mycobacterial disease: case report and review of the literature  
N.L. Wong |

The poster viewing session will take place during the lunch break on Thursday 7th July.
### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>PD01</td>
<td>Homocysteine levels in blood and the severity of vitiligo before and after narrowband ultraviolet B phototherapy</td>
<td>J. Taneja, T.C. Arora, V. Ramesh and C. Kaur</td>
</tr>
<tr>
<td>08:45</td>
<td>PD02</td>
<td>Modest response in vitiligo to excimer lamp targeted therapy, using a once-weekly dosage protocol over a 20-week treatment period</td>
<td>S. Ayob, S. Cockayne and D. Gawkrodger</td>
</tr>
<tr>
<td>09:00</td>
<td>PD03</td>
<td>Upregulation of matrix metalloproteinase 12 and its activity by ultraviolet A1 in human skin: potential implications for human health.</td>
<td>A. Tewari, R. Sarkany and A. Young</td>
</tr>
<tr>
<td>09:15</td>
<td>PD04</td>
<td>Cochrane systematic review: interventions in polymorphic light eruption</td>
<td>T. Ling, C. Cunningham, S. Rhodes, R. Dawe and L. Rhodes</td>
</tr>
<tr>
<td>09:30</td>
<td>PD05</td>
<td>Factors predicting response to treatment and disease recurrence following topical photodynamic therapy for primary Bowen disease and basal cell carcinoma</td>
<td>R. Hambly, N. Mansoor, C. Quinian, Z. Shah, N. Ralph and F.J. Moloney</td>
</tr>
<tr>
<td>10:45</td>
<td>PD08</td>
<td>The impact of intraregional variation in ultraviolet B phototherapy protocols on psoriasis clearance</td>
<td>R. Waas, V. Armstrong and S. Weatherhead</td>
</tr>
<tr>
<td>11:15</td>
<td>PD09</td>
<td>Guest Lecture: Daylight PDT</td>
<td>Dr Sally Ibbotson (Dundee)</td>
</tr>
<tr>
<td>11:25</td>
<td>PD10</td>
<td>Congenital erythropoietic porphyria: mild presentation with late onset associated with a uroporphyrinogen III synthase enzyme gene promoter sequence mutation</td>
<td>A. Fityan and R. Sarkany</td>
</tr>
<tr>
<td>11:35</td>
<td>PD11</td>
<td>A case of photosensitive trichothiodystrophy with mutations in the ERCC2 (xeroderma pigmentosum) gene highlighting classical features and new classification</td>
<td>T. Tull, S. Mohammed, R. Sarkany, A. Lehmann and H. Fassihi</td>
</tr>
<tr>
<td>11:45</td>
<td>PD12</td>
<td>The impact of intraregional variation in ultraviolet B phototherapy protocols on psoriasis clearance</td>
<td>R. Waas, V. Armstrong and S. Weatherhead</td>
</tr>
<tr>
<td>12:00</td>
<td>PD13</td>
<td>AGM</td>
<td></td>
</tr>
</tbody>
</table>

### POSTERS

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD09</td>
<td>Can the Psoriasis Area Severity Index score measured 4 weeks into a course of narrowband ultraviolet B phototherapy be used to predict final Psoriasis Area Severity Index response?</td>
<td>J. Fowler and S. Weatherhead</td>
</tr>
<tr>
<td>PD12</td>
<td>Mersey and North Wales regional phototherapy audit 2016</td>
<td>G. Hill and E. Davies</td>
</tr>
<tr>
<td>PD13</td>
<td>Knowledge, behaviour and attitudes of patients with skin cancer towards national recommendations on sunlight exposure and vitamin D</td>
<td>D. Rutkowski, M. Farrar, A. Webb and L. Rhodes</td>
</tr>
<tr>
<td>PD14</td>
<td>Cutaneous lupus erythematosus improved by sunlight</td>
<td>M. Lynch, R. Sarkany, E. Benton, D. D’Cruz, S. Sangle and David McGibbon</td>
</tr>
</tbody>
</table>
| PD15 | Recurrent sun-triggered lymphocytoma on calf with polymorphic light eruption, solar fatigue, enthesitis/polychondritis and benign follicular hyperplasia of the thymus  
A. Abdul-Wahab, R. Sarkany, H. Fassihi, B. Martin, D. D'Cruz, S. Sangle and D. McGibbo |
| PD16 | Four cases of intralesional blisters arising during TL01 ultraviolet B phototherapy for chronic plaque psoriasis  
B. Murphy and K. McKenna |

The poster viewing session will take place between 12:30 and 13:00 on Thursday 7th July.
## UK TREND

**Date:** Thursday 7th July  
**Time:** 08:30-10:00  
**Room:** Hall 10  
**Chairs:** Professor Nick Reynolds & Professor Eugene Healy

### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 08:45</td>
<td>UK01</td>
</tr>
<tr>
<td>08:45 – 09:00</td>
<td>UK02</td>
</tr>
<tr>
<td>09:00 – 09:15</td>
<td>UK03</td>
</tr>
<tr>
<td>09:15 – 09:30</td>
<td>UK04</td>
</tr>
<tr>
<td>09:30 – 09:45</td>
<td>UK05</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Discussion Session</td>
</tr>
</tbody>
</table>

**UK01**  
*Introduction to UK TREND*  
Professor Nick Reynolds (Newcastle)

**UK02**  
*A Wellcome Trust Senior Fellowship - how UK TREND supported my application*  
Professor Sara Brown (Dundee)

**UK03**  
*The TREATment of severe Atopic eczema in children Trial (TREAT): an update*  
Dr Carsten Flohr (London)

**UK04**  
*The APRICOT trial: clinical and mechanistic studies of IL-1 signalling in pustular psoriasis*  
Dr Francesca Capon (London)

**UK05**  
*An update / an introduction to the UK TREND non-melanoma skin cancer initiative*  
Professor Eugene Healy (Southampton)

### NOTES

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---
Registrars Symposium

Date: Thursday 7th July  
Time: 10:45 – 12:15  
Room: Hall 1  
Chairs: Dr Michael Ardern-Jones & Dr Vincent Li

<table>
<thead>
<tr>
<th>Time</th>
<th>Schedule</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 – 11:00</td>
<td>RF01</td>
<td>Owning cats or dogs is associated with protection from food allergy and increased diversity of infants’ faecal microbiota at 3 months</td>
<td>T. Marrs, M. Perkin, A. Witney, D. Rivett, J. Craven, K. Logan, K. Bruce, D. Strachan, G. Lack and C. Flohr</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>RF02</td>
<td>Horizon planning for nonmelanoma skin cancer in the U.K.: estimated cases for 2020 and 2025</td>
<td>P. Goon, L. Igali, D. Greenberg and N. Levell</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>RF03</td>
<td>‘Psoriasis direct’ service</td>
<td>E. Ormerod, T. Bale and N. Stone</td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td>RF04</td>
<td>Investigating lymph node involvement in mycosis fungoides: optimizing the balance between benefit and harm</td>
<td>A. Spencer, P. Gazzani and J. Scarisbrick</td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td>RF06</td>
<td>The cellular and molecular effects of UVA1 on human skin in vivo: impact on human health</td>
<td>A. Tewari</td>
</tr>
</tbody>
</table>

NOTES
**British Hair and Nail Society**

**Date:** Thursday 5th July  
**Time:** 10:45 – 12:15  
**Room:** Hall 10  
**Chairs:** Dr Paul Farrant, Dr Matthew Harries & Dr Susan Holmes

### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55 – 11:05</td>
<td>BH02</td>
<td>A nail curriculum for secondary care: a review of teledermatology nail referrals received over 11 years in a specialist centre</td>
<td>B. Wright and D. DeBerker</td>
</tr>
<tr>
<td>11:05 – 11:15</td>
<td>BH03</td>
<td>Hair changes associated with BRAF inhibitor therapy: a case series</td>
<td>M. Fitzgerald and L. Fearfield</td>
</tr>
<tr>
<td>11:15 – 11:45</td>
<td>BHGL</td>
<td>Guest Lecture: The Hair Research Priority Process, Results and Next Steps</td>
<td>Dr Abby Macbeth (Norwich)</td>
</tr>
<tr>
<td>11:45 – 11:55</td>
<td>BH04</td>
<td>Clinical efficacy and tolerability of hydroxychloroquine in the treatment of lichen planopilaris: a single-centre retrospective study</td>
<td>E.N. Dhonncha, C. Foley and T. Markham</td>
</tr>
<tr>
<td>11:55 – 12:05</td>
<td>BH05</td>
<td>Four-year data on the use of topical immunotherapy with diphenylcyclopropenone when it all falls out: more than just a last resort</td>
<td>S. Mirhadi and A. Abdullah</td>
</tr>
<tr>
<td>12:05 – 12:15</td>
<td>BH06</td>
<td>Clarithromycin, rifampicin and fusidic acid combination therapy for folliculitis decalvans</td>
<td>G.A. Fremlin and M.R. Kaur</td>
</tr>
</tbody>
</table>

### POSTERS

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>BH07</td>
<td>Transillumination: a useful auxiliary tool for the noninvasive diagnosis of all clinical variants of digital mucous cysts</td>
<td>E. Errichetti and D. de Berker</td>
</tr>
<tr>
<td>BH08</td>
<td>Two different cases and causes of onychoheterotopia in children</td>
<td>L. Fuller, A. Shah, K. Mallawaarachchi, A. Karim and R. Suchak</td>
</tr>
<tr>
<td>BH09</td>
<td>Retronychia following pregnancy</td>
<td>R. Waas, T. Mestre, T. Oliphant, L. Speight and J. Langtry</td>
</tr>
<tr>
<td>BH10</td>
<td>Microsporum canis presenting as female pattern hair loss in an immunosuppressed patient</td>
<td>D. O’Callaghan and P. Farrant</td>
</tr>
<tr>
<td>BH11</td>
<td>Coexistence of frontal fibrosing alopecia and discoid lupus erythematosus: a true association?</td>
<td>A. Wernham, R. Muc and M. Kaur</td>
</tr>
<tr>
<td>BH12</td>
<td>Laser hair depilation: a potential treatment option for severe recalcitrant folliculitis decalvans</td>
<td>V. Van-de-Velde, S. Aguilar-Duran, M. Tidman and M. Mowbray</td>
</tr>
<tr>
<td>BH13</td>
<td>A rare case of spontaneous repigmentation of previously white hair</td>
<td>A. Shah, L. Fuller and S.L.P Chong</td>
</tr>
<tr>
<td>BH14</td>
<td>Pattern hair loss in men is not always androgenetic</td>
<td>S. Nassar, S. Zaheri, R. Ramakrishnan and I. Ali</td>
</tr>
<tr>
<td>BH15</td>
<td>Lichen planopilaris after hair transplant: a diagnostic and therapeutic challenge</td>
<td>A. Jamil and S. Cockayne</td>
</tr>
<tr>
<td>BH17</td>
<td>An unusual case of frontal fibrosing alopecia in an Asian British woman presenting with facial hyperpigmentation</td>
<td>D.M. Caruana, M. Paul and S. Holmes</td>
</tr>
</tbody>
</table>

*The poster viewing session will take place between 12:30 and 13:00 on Thursday 7th July*
BADGEM Clinical Meeting

Date: Thursday 7th July  
Time: 13:15-17:30  
Room: Hall 5  
Chairs: Professor Irene Leigh  
Professor Sara Brown

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 – 13:20</td>
<td>Welcome BADGEM Clinical Meeting – Professor Irene Leigh</td>
</tr>
</tbody>
</table>
Lessons from EB-CLINET - A clinical network for a rare disease  
Professor Johann Bauer (Salzburg, Austria) |
| 13:45 – 13:55 | BG01 Lessons learnt from the design and development of a multicentre rare genetic skin disease research study  
S. Tso, J. Simpson, M. Martinez-Queipo, E. Glass and J. McGrath |
| 13:55 – 14:05 | BG02 Vulvovaginal symptoms in women with epidermolysis bullosa  
E. Orrin, N. Alband, A. Abdul-Wahab, E. Wedgeworth and J. Mellerio |
| 14:05 – 14:30 | Invited Talk  
Cutis laxa: the journey to a clinical nosology  
Professor Bert Callewaert (Ghent, Belgium) |
| 14:30 – 15:15 | Break  
Rook Oration  
Hall 4  
Focus Sessions |
| 16:00 – 16:25 | Invited Talk  
Hereditary Cancer as seen from the outside  
Sir John Burn (Newcastle) |
| 16:25 – 16:35 | BG03 Genetic and phenotypic heterogeneity in Ferguson–Smith disease: a case series  
Z. Shukur, D. Goudie, N. Chung, S. Whittaker, A. Shaw and K. Lacy |
| 16:35 – 16:45 | BG04 Cutaneous hyperpigmentation and familial gastrointestinal stromal tumour associated with c-KIT mutation  
G. Wall, D. Halliday, J. Dua, E. Jeremia, T. McPherson and R. Matin |
| 16:45 – 17:10 | Invited Talk  
Dysmorphology in the sequencing era; clinicians still have a role  
Professor Dian Donnai (Manchester) |
| 17:10 – 17:20 | BG05 Novel mutations in SLURP1 causing Mal de Meleda palmoplantar keratoderma with varying phenotypes  
| 17:20 – 17:30 | BADGEM Initiatives  
Dr Neil Rajan (Newcastle) & Dr Simon Tso (London) |

POSTERS

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>BG06</td>
<td>Mild arthrogryposis, renal dysfunction and cholestasis syndrome caused by a novel splice site mutation in VPS33B</td>
<td>A. Ahmed, L. McGinty, D. Blaydon, D. Kelsell, E. O’Toole and B. De Silva</td>
</tr>
<tr>
<td>BG07</td>
<td>Tracking tumour kinetics in patients with germline CYLD mutations</td>
<td>S. Brown, S. Worthy, S. Barnard, J. Langtry and N. Rajan</td>
</tr>
<tr>
<td>BG08</td>
<td>FOXN1 duplication and congenital hypertrichosis: a case report</td>
<td>E. Gilhooley, C. Feighery and S. Collins</td>
</tr>
<tr>
<td>BG09</td>
<td>Will a genetic diagnosis of poikiloderma with neutropenia influence management?</td>
<td>S. El-Heis, M. Ardern-Jones and K. Godfrey</td>
</tr>
<tr>
<td>BG10</td>
<td>A dramatically different case of Dowling–Degos disease</td>
<td>S. Sherif, N. Spiereings, R. Betz, H. Chong and M. Singh</td>
</tr>
<tr>
<td>BG12</td>
<td>Terminal osseous dysplasia with pigmented defects</td>
<td>S. H. Foo, R. Goodwin, A. Rawlinson, V. Jones, A. Fry and C. Moss</td>
</tr>
</tbody>
</table>
| BG13 | Multiple well-differentiated squamous cell carcinomas: a case of Ferguson–Smith disease and a review of the literature for use of acitretin in this condition  
A. Lowe, W.A. Woo, L. Atkinson and E. Topham |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BG14 | Dermatologists play a key role in diagnosing LEOPARD syndrome  
S. Mirhadi, H. Fassihi, L. Islam and R. Ramesh |
| BG15 | Brooke–Spiegler syndrome: an unusual presentation with a novel underlying mutation  
S. Whitaker and J. Hughes |
| BG16 | An interesting case of LEOPARD syndrome  
S. Krishna, J. Natkunarajah and A. Fogo |

The poster viewing session will take place during the lunch break on Thursday 7th July
**Plenary & CPD Session**

**Date:** Thursday 7th July  
**Time:** 13:15-17:30  
**Room:** Hall 1  
**Chairs:** Dr Nick Levell & Dr Richard Weller  
Dr Ruth Murphy & Dr Mark Griffiths

### PROGRAMME

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 – 13:45</td>
<td>Keynote Lecture - Introduced by Dr Nick Levell</td>
</tr>
<tr>
<td></td>
<td><strong>Recent advances in vasculitis</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr Chetan Mukhtyar (Norwich)</em></td>
</tr>
<tr>
<td></td>
<td>The vasculitides are a myriad of conditions united by inflammation of the vessel wall. The different vasculitis syndromes have different pathogenetic mechanisms, treatments and outcomes. This talk will explore the major changes in our understanding of these conditions.</td>
</tr>
<tr>
<td></td>
<td><strong>Nomenclature</strong></td>
</tr>
<tr>
<td></td>
<td>There has been a renaming of the various vasculitis syndromes and all the pure cutaneous vasculitis syndromes have been grouped under the broad umbrella of ‘single organ vasculitis’. There were no dermatologists at the international conference where the nomenclature was revised. We have suggested adapting this modification to include the well-defined cutaneous vasculitides. The incidence of cutaneous leukocytoclastic vasculitis between 1996 and 2010 was reported to be about 4.5 / 100,000 person years. In a review of 766 patients with cutaneous vasculitis, 60 cases met the definition of ‘single organ vasculitis’. Typically, these cases have a good outcome with spontaneous resolution in 73%. This may reflect the rarity of the specific cutaneous vasculitis syndromes like Erythema elevatum diutinum, granuloma faciale and cutaneous arteritis.</td>
</tr>
<tr>
<td></td>
<td><strong>Treatment</strong></td>
</tr>
<tr>
<td></td>
<td>ANCA associated vasculitis do not have a benign prognosis and cyclophosphamide and rituximab have become comparable mainstream treatments for inducing remission. Traditionally, azathioprine has been the mainstay of remission maintenance treatment for these conditions. In a randomized controlled trial of 115 patients, rituximab at 6 month intervals was superior to a reducing dose of azathioprine in maintaining remission. This data needs replication before rituximab can completely replace azathioprine. It has been common practice to use glucocorticoids for treating ‘minor’ relapses but there is emerging evidence that this simply pushes the problem into the future. 70% of ‘minor relapses’ treated with glucocorticoid escalation alone relapse again at a mean of 9.4 months and end up receiving a larger cumulative dose of prednisolone.</td>
</tr>
<tr>
<td></td>
<td><strong>Follow-up</strong></td>
</tr>
<tr>
<td></td>
<td>Glucocorticoids are toxic. There is fresh data emerging that ‘damage’ in ANCA associated vasculitis is independently associated with higher cumulative glucocorticoid use. In large vessel vasculitis like giant cell arteritis, glucocorticoids form the main thrust of treatment. In a longitudinal study of 3408 patients with GCA there was a long term increase in the risk of cardiovascular and cerebrovascular events (Hazard ratio of 1.7) compared to controls. Glucocorticoids are probably to blame for this increase. The risk of cancer in patients with ANCA associated vasculitis has been assessed using Dutch and Danish registries – and both have independently shown non-melanoma skin cancers are the single largest cause of the increased malignancy risk.</td>
</tr>
<tr>
<td></td>
<td><strong>Recommendations</strong></td>
</tr>
<tr>
<td></td>
<td>Well conducted large clinical trials in ANCA associated vasculitis have made it possible to form evidence based recommendations. The British and the European rheumatology societies have presented recommendations which will also be shared in this talk.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13:45 – 14:05</th>
<th>Invited Lecture</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Clinical Trial Design: why is it important?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Professor Kim Thomas (Nottingham)</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14:05 – 14:25</th>
<th>Invited Lecture</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Ethnic Dermatology: A Pathway To Study Human Cutaneous Diversity</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr Ophelia Dadzie (London)</em></td>
</tr>
</tbody>
</table>
Thur 7 July

14:25 – 15:10

Arthur Rook Oration – Introduced by Dr Nick Levell

**Genetic medicine in dermatology – from mutation to modulation and medication**
Professor Irwin McLean (Dundee)

The last twenty five years has seen tremendous advances in the identification of genetic defects that drive hereditary skin diseases, skin cancer and complex dermatological traits such as psoriasis and atopic dermatitis. In many cases, the mechanism(s) by which these genetic mutations are translated into the disease pathology observed in the clinic is unclear. Generation and characterization of humanized transgenic animal models is invaluable in dissecting the biochemical and signaling pathways that are dysregulated in disease, as well as providing a platform for the development and testing of experimental medicines to treat skin diseases. My laboratory has been heavily involved in identification and functional analysis of genes involved in inherited disorders of keratinization and atopic eczema. Along the way, we have developed a number of realistic animal models of skin disorders and have identified a number of tractable pathways that we are exploiting for the development of new therapies. The latter is now the main focus of the laboratory, where we are applying state-of-the-art drug academic discovery technologies to therapy development in dermatology.

15:10 – 15:30 Break Hall 4

15:30 – 16:00 Focus Sessions – see page 66

16:00 – 16:15 CPD01

**What's new in melanoma**
Professor Julia Newton-Bishop (Leeds)

16:15 – 16:30 CPD02

**What's new in Paediatric Dermatology**
Professor Celia Moss (Birmingham)

16:30 – 16:45 CPD03

**What's new in non-melanoma and skin cancers**
Professor Catherine Harwood (London)

16:45 – 17:00 CPD04

**What is new in Cutaneous Lymphoma**
Sean Whittaker (London)

17:00 – 17:15 CPD05

**What's new in atopic dermatitis**
Professor Mike Cork (Sheffield)

17:15 – 17:30 CPD06

**What's new in Tropical Dermatology**
Dr Rachael Morris-Jones (London)

NOTES
Focus Sessions

Date: Thursday 7th July
Time: 15:30-16:00
Room: Hall 6

**Dermatomyositis: clinical phenotypes and associated autoantibodies**

<table>
<thead>
<tr>
<th>TIME</th>
<th>PROGRAMME</th>
<th>TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-16:00</td>
<td>FS1</td>
<td>Dermatomyositis: clinical phenotypes and associated autoantibodies</td>
<td>Dr Simon Meggitt (Newcastle)</td>
</tr>
</tbody>
</table>

Date: Thursday 7th July
Time: 15:30-16:00
Room: Hall 10

**Management Controversies in SJS/TEN**

<table>
<thead>
<tr>
<th>TIME</th>
<th>PROGRAMME</th>
<th>TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-16:00</td>
<td>FS2</td>
<td>Management Controversies in SJS/TEN</td>
<td>Dr Daniel Creamer (London)</td>
</tr>
</tbody>
</table>

Date: Thursday 7th July
Time: 15:30-16:00
Room: Hall 9
Chair: Dr Tabi Leslie

**Urticaria Past, Present and Future**

<table>
<thead>
<tr>
<th>TIME</th>
<th>PROGRAMME</th>
<th>TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-15:38</td>
<td>FS3</td>
<td>Past</td>
<td>Dr Tabi Leslie (London)</td>
</tr>
<tr>
<td>15:38-15:46</td>
<td>FS3:1</td>
<td>Present</td>
<td>Dr Chris Rutowski (Cambridge &amp; London)</td>
</tr>
<tr>
<td>15:46-15:54</td>
<td>FS3:2</td>
<td>Future</td>
<td>Dr Clive Grattan (Norwich &amp; London)</td>
</tr>
<tr>
<td>15:54-16:00</td>
<td></td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Hot Topics

They will be semi-informal set-up taking place in two designated areas within the Exhibition Hall 3 during breaks. These are highlighted as HT1 and HT2 on the exhibition plan.

| TUESDAY 5TH JULY – morning break | 10:30 – 11:00 | HT1  | Rosacea  
|                                  |                |      | Dr Ed Seaton  
| 10:30 – 11:00                   | HT2  | Is there any benefit of sentinel lymph node biopsy in cutaneous squamous cell carcinoma?  
|                                  |      |      | Prof Michael Veness  

| TUESDAY 5TH JULY – afternoon break | 14:30 – 15:00 | HT1  | Metastatic Melanoma  
|                                  |                |      | Dr Louise Fearfield  
| 14:30 – 15:00                   | HT2  | Useful histological clues to subtle blistering disorders  
|                                  |      |      | Dr Saleem Taiblee  

| WEDNESDAY 6TH JULY – morning break | 10:30 – 11:00 | HT1  | Adverse Events to Cosmetic Procedures: what every dermatologist must know  
|                                  |                |      | Dr Tamara Griffiths  
| 10:30 – 11:00                   | HT2  | What’s new in eczema prevention and treatment?  
|                                  |      |      | Dr Carsten Flohr  

| WEDNESDAY 6TH JULY – afternoon break | 15:30 – 16:00 | HT1  | Engaging Body dysmorphic patients to accept treatment  
|                                  |                |      | Dr Janet Angus  
| 15:30 – 16:00                   | HT2  | What’s New in Paediatric Dermatology  
|                                  |      |      | Dr Veronica Kinsler  

| THURSDAY 7TH JULY – morning break | 10:15 – 10:45 | HT1  | Penile biopsy  
|                                  |                |      | Dr David de Berker  
| 10:15 – 10:45                   | HT2  | Graft vs Host Disease  
|                                  |      |      | Dr Fiona Child  

Pharma Workshop

They will be semi-informal set-up taking place in designated areas within the Exhibition Hall 3 during breaks. These are highlighted as HT1 on the exhibition plan.

| TUESDAY 5TH JULY – lunchtime break | 12:15 – 12:30 | HT1  | (LEO Pharma) Introducing Enstilar® - an innovation in the delivery of topical combination treatment for plaque psoriasis  
|                                  |                |      | Dr Kasper Noerremark  
| 12:30 – 12:45                   | HT1  | (Stiefel, a GSK Company) Antibiotic Resistance in Acne Management  
|                                  |                |      | Dr Alexandra Marta  
| 12:45 – 13:00                   | HT1  | (Shire) Dermatological Manifestations in Fabry Disease  
|                                  |                |      | Dr Cate Orteu  

| THURSDAY 7TH JULY – lunchtime break | 12:30 – 12:45 | HT1  | (Stiefel, a GSK Company) Retinoids in Dermatology: A review of pregnancy prevention in Chronic Hand Eczema  
|                                  |                |      | Dr Myooran Sithamparanathan  
| 12:45 – 13:00                   | HT1  | (LEO Pharma) Introducing Enstilar® - an innovation in the delivery of topical combination treatment for plaque psoriasis  
|                                  |                |      | Dr Kasper Noerremark  
| 13:00 – 13:15                   | HT1  | (Celgene) Apremilast Case Studies  
|                                  |                |      | Professor Shernaz Walton  


Hand Eczema Assessment Tool Training Session

Date: Wednesday 6th July
Time: 17:00 – 17:30
Room: Executive 8

Date: Thursday 7th July
Time: 14:00 – 14:30
Room: Executive 8

This session will run twice on the above days. This session is open to all health care professionals.

Presenters: Dr Miriam Wittmann, Chief Investigator ALPHA study
Dr Anna Keszegpal, Clinical Research Fellow/Study coordinator ALPHA Study

Several instruments for the assessment of the severity of hand eczema have been developed. Their accurate use has a great importance in everyday clinical practice and trials on hand eczema.

Learning Objectives:
To offer a short training session where participants can acquire theoretical knowledge on the most widely used hand eczema assessment tools PGA (Physicians Global Assessment), mTLSS (modified Total Lesion Symptom Score) and HECSI (Hand Eczema Severity Index) and develop practical skills. This session is open to all health care professionals.
Poster Presentations

These presentations will take place in Hall 4. Please see the abstract supplement for full abstracts in poster number order.

### Tuesday 5th July

<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Detail</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:47</td>
<td>PP2</td>
<td>(Poster 35) Spontaneous regression of skin lesions. What have I missed? E.V. Wray, A.J. Waters and C.J. Fleming</td>
<td>Hall 4</td>
</tr>
</tbody>
</table>

### Wednesday 6th July

<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Detail</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>PP5</td>
<td>(Poster 76) Current status of observations of malignancies in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study D. Fiorentino, M. Lebwohl, V. Ho, R. Langley, K. Goyal, S. Fakharzadeh, S. Calabro and W. Langhoff</td>
<td>Hall 4</td>
</tr>
<tr>
<td>10:36</td>
<td>PP6</td>
<td>(Poster 90) Improvement in the quality of life of patients with severe plaque psoriasis treated with systemic methotrexate in fixed doses of 10 mg or 25 mg orally once weekly: a prospective, randomized, double-blind, parallel-group study C.V. Krishna and A.V.M. Rao</td>
<td>Hall 4</td>
</tr>
<tr>
<td>10:42</td>
<td>PP7</td>
<td>(Poster 92) Secukinumab achieved ≥90% improvement in Psoriasis Area and Severity Index at weeks 16 and 52 in many patients with no or partial response at week 12 R. Williams, M. Tomlinson, Y. Armendariz and F. Allen</td>
<td>Hall 4</td>
</tr>
</tbody>
</table>

### Thursday 7th July

<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Detail</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td>PP11</td>
<td>(Poster 98) Systemic therapy for vulval erosive lichen planus (the ‘hELP’ Trial): a pilot randomized controlled trial R. Simpson, R. Murphy and K. Thomas</td>
<td>Hall 4</td>
</tr>
</tbody>
</table>
The Special Interest Group posters are situated within hall 4. Posters P01 - P116 will be positioned on the balcony of the exhibition hall. The poster viewing session will take place during the lunch breaks on Tuesday (even numbered posters) and Thursday (odd numbered posters). All presenting authors have been asked to stand by their posters at this time. There will also be an e-poster display on the balcony of the exhibition hall.

**Clinicopathological Cases**

**P01** Disseminated *Mycobacterium marinum* infection  
D. Keith, F. Tasker, G. Melling, S. Rajan, C. Wildek, K. Miller, E. Clark, M. Jenkins, A. Bray, S. Narayan, K. Finucane, B. Bovill and A. Darvay

**P02** Cutaneous amyloid deposition following a lichenoid drug eruption  
C. Foley, M. Moran, C. Gallagher, A. Fabre, K. Sheahan and A. Lally

**P03** Persistent and progressive purpura in a patient on long-term care  
J. Boggs, C. Foley and M. Laing

**P04** Sweet syndrome–pyoderma gangrenosum overlap as a presenting symptom of acute Crohn colitis in a patient with seronegative spondyloarthropathy  
J. Boggs and M. O’Kane

**P05** Cutaneous features of granulomatosis with polyangiitis presenting after diagnosis of systemic disease and during maintenance therapy with azathioprine  
G. Haebich, R. Katugampola, W. Patterson and K. May

**P06** Idiopathic palisaded neutrophilic and granulomatous dermatitis  
R. Karumanchery, A. Bakshi, R. Carr and W. Farrar

**P07** Poster withdrawn

**P08** Metastatic epithelioid angiosarcoma  
D. Keith, M. Sanderson, K. Gane, B. Wright, T. Wells, W. Neary, A. Dangoor, N. Bhatt and J. Sansom

**P09** A novel triad: invasive dermatophyte infection with *Trichophyton interdigitale*, acquired reactive perforating collagenosis and associated signal transducer and activator of transcription 3 mutation  
J. Simpson, S. Seneviratne, D. Lowe, B. Grimbacher, M. Brown and L. Fearfield

**P10** A long-standing nodule on the chin: could it be a squamous cell carcinoma?  
S. Ziaj, D. Markiewicz, R. Cerio, A. Ekeowa-Anderson and K. Gibbon

**P11** Disseminated tuberculosis masquerading as a nonhealing oral ulcer  
R. Bhatia, R. Mahajan, S. Arava, S. Singh and D. Kandasamy

**P12** Pruritic translucent papules, joint pains and giant cells: a case of multicentric reticulohistiocytosis  
C. Peng, S. Karanovic, C. Allen, C. Bell and J. Powell

**P13** Squamous transformation in cutaneous Crohn disease  
S. Kirthi and A.-M. Tobin

**P14** Reticular erythematous mucinosis: two cases treated with mepracrine  
N. Spierings, E. Raweily and F. Aslanian

**P15** Paraneoplastic cherry angiomata  
N. Spierings, F. Worsnop and J. Soo

**P16** A hole in one: a case of severe unilateral vulval ulceration in a young woman  
S. Keegan and R. Katugampola

**P17** Cutaneous angiosarcoma of the chest wall post-trauma  
L. Roche, M. Lynch, B. Ramsay, K. Ahmad, D. Wall and C. Hackett

**P18** A case of genital pyoderma gangrenosum successfully treated with ciclosporin without relapse of established follicular lymphoma, and a review of relevant existing literature  
L. Roche, C. Gulman and M. O’Kane

**P19** A suppurative infection with subsequent scarring: possibly the first reported case of canine-to-human transmission of *Trichophyton mentagrophytes* var. *erinacei*  
B. McDonald and C. Vlachou

**P20** Rosai–Dorfman disease: successful treatment with methotrexate  
A. Dubois, P. Sloan and M. Haniffa

**P21** Malignant peripheral nerve sheath tumour presenting in neurofibromatosis type 1  
L. Nestor, R. Hellen, B. Moriarty and A. Fabre

**Education, Training, Service, Audit**

**P22** Prescribing for acne in the U.K.: patterns and influencers  

**P23** Is there a dermatologist in the house? A 1-year review of dermatology inpatient activity in a district general hospital  
N. Dinani, E. McNulty-Brown and A. Woollons

**P24** Evaluation of the IMPACT study practitioner training intervention: using motivational interviewing to optimize self-management in psoriasis  

**P25** Proposal for National Dermatology Surgery Safety Standards: development of a dermatology surgery standard operating policy with mandatory training of staff may be an important tool to prevent wrong-site surgery  
R. Bhutani, C. Machin, G. Stables, V. Goulden and A. Mitra

**P26** The Facebook effect: using digital technology and social media to increase research participation from teenagers and healthcare professionals  
H.J. Whitehouse, S. Lock, T.W. Slack and A.M. Layton

**P27** Detecting psoriatic arthritis in patients with psoriasis: does an educational leaflet improve attendance for screening?  
L. Savage, L. Coates, A. Moverley and P. Hellwell
General Dermatology

P34 Dermatology-led lower-limb cellulitis service: analysis of 1579 referrals
A. Lee, D. Nelson and N. Leveill

P35 Spontaneous regression of skin lesions. What have I missed?
E.V. Wray, A.J. Waters and C.J. Fleming

P36 How scratching can take its Toll on itch: new mechanistic insights into innate immune sensitization
I. McDonald, A.G. Szollosi, I.L. Szabo, B. Kirby and M. Steinhoff

P37 Severe cutaneous drug hypersensitivity reactions to vancomycin and teicoplanin
W.Y. Haw, M.E. Polak, C. Mcguire and M. Arden-Jones

P38 Impact of biological therapies on risk of major adverse cardiac events in patients with psoriasis: a meta-analysis of randomized controlled trials
W. Rungapiromnan, R. Warren, Z. Yiu, C.E.M. Griffiths and D. Ashcroft

P39 Fatal disseminated cowpox virus infection in an immunosuppressed adolescent

P40 Chronic inflammatory conditions carry a similarly higher cardiovascular risk compared with the general population and warranting screening
S. Kirthi, M. Hussey, A.-M. Tobin and D. McNamara

P41 Hanssen disease: a biochemical perspective and insight into the role of antioxidants
V. Chuah, A. Mistry and D. Umrigar

P42 The profile and secondary-care management of U.K. patients with hidradenitis suppurativa: interim results from a multicentre observational cross-sectional study

P43 Spectrum of granuloma annulare: a retrospective clinicopathological study
P. Saraogi, U. Khopkar and S. Mahajan

P44 A dynamic landscape of allergen associations in delayed-type cutaneous hypersensitivity
M. Lynch, J. White, J. McFadden, I. White and P. Banerjee

P45 Impact of alexithymia and disease characteristics on work productivity and activity in patients with psoriasis with short disease duration: EPIDENOS multicentre study

P46 Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective study of epidemiology and clinical course
P. Saraoji, S. Mahajan and U. Khopkar

P47 Frontal fibrosing alopecia in men: an association with leave-on facial cosmetics and sunscreens

P48 Can the new contest questionnaire identify psoriatic arthritis in patients with psoriasis in a primary-care population?
L. Savage, L. Coates, A. Caperon and P. Helliwell

P49 Twenty-year review of congenital absence of skin presenting to a paediatric dermatology department
D. Sathishkumar, J. Kainth, C. Moss and M. Ogbo

P50 Vulvovaginal symptoms in women with epidermolysis bullosa
E. Orin, N. Alband, A. Abdul-Wahab, E. Wedgeworth and J. Mellerio

P51 Insulin resistance and metabolic syndrome in acne
M. Nagpal

P52 Psoriasis and carotid artery intima–media thickness
P. Raj R and D. Hazarika

P53 A novel OSMR mutation in familial primary localized cutaneous amyloidosis in a British white family
R. Adams, C. Colmont, D. Hausa and G. Patel

P54 Psychological distress in patients with hidradenitis suppurativa
S. Kirthi, R. Hellen, R. O’Connor, M. Connolly and A.-M. Tobin

P55 Obesity, low mood, negative beliefs about illness and severity of psoriasis are linked to dysfunctional eating patterns
C. Bundy, C. Pearce, J. Sergent and C.E.M. Griffiths

P56 Diurnal and seasonal variation in psoriasis symptoms
F. Ferguson, A. Henry, H. Hunter, C. Bundy, C.E.M. Griffiths and E. Kleyn

P57 An automated noninvasive method for skin-surface integrity analysis
O.S. Osman, K. Naidoo, V. Batiaille, S. Jassim, K. Langlands and J. Selway

P58 A systematic review of dermatological complications following male genital piercing
A. Daunton and M. Shah

P59 Pulsed-dye laser treatment of paediatric port-wine stains: variation of practice in the U.K. National Health Service
M. Beattie, D. Widdowson and W. Anderson
P60  Evaluation of the relationship between aquaporin-9 and microRNA-205 expression in psoriatic epidermis
T.H. Tan, P.D. Yesudian, L. West, A. Al-Sharqi, R. Parslew and K. Ross

P61  Renal function in hidradenitis suppurativa: a retrospective cohort study of a tertiary-referral hidradenitis suppurativa clinic
L. Jennings, M. Canney, R. Hughes, B. Moriarty and B. Kirby

P62  The role of beliefs, mood, coping strategies, disease severity and quality of life in patients living with psoriatic arthritis
L. Howells, A. Chisholm, S. Cotterill, H. Chinoy, R. Warren and C. Bundy

P63  Study of transcription factor Ets-1 and adhesion molecules in vitiligo
N. Srivastava, S. Bhardwaj, S. Rani, R. Kumar and D. Parsad

P64  A systematic review of the impact on quality of life of interventions for psoriasis
F. Ali, A. Cueva, J. Vyas, V. Piguet, S. Salek and A. Finlay

P65  Highly sensitive C-reactive protein as a biomarker of cardiovascular risk in psoriasis

P66  Tattoos and magnetic resonance imaging: a ‘burning’ issue
P.S.A. Jayasekara, S. Balasubramaniam, A. Fonia and P.D. Yesudian

P67  Noonan syndrome with multiple lentigines identified by next-generation sequencing
B. McDonald, M. Amieva, D.P. Kelsell, E.A. O’Toole, E. Burkett-Wright, B. Kerr and K. Batta

P68  Are we sitting on a leprosy time bomb? Where do we stand a decade after leprosy elimination in India?
S. Deb

P69  Should leprosy be given a backseat in the postelimination era?
A. Arora, T. Narang and S. Dogra

P70  Pulmonary cylindromas in CYLD cutaneous syndrome
S. Brown, S. Barnard, J.A.A. Langtry, S.A. Worthy, C. Bloxham, P.S. Loo, A. Husain and N Rajan

P71  A complex case of necrotizing scleritis and acne conglobata
G. Fremlin, A. Wernham, A. Patel and S. Orpin

P72  What’s that smell?
G. Fremlin, K. Martin and J.M.R. Goulding

P73  Senescence in dermal fibroblasts and its implication in the pathogenesis of vitiligo
S. Rani, D. Prasad, S. Bhardwaj, N. Srivastava, V.L. Sharma and R. Kumar

P74  Comparative study of trichoscopy findings in female pattern androgenic alopecia and chronic telogen effluvium
V. Chugh

P75  Four-year data on the use of topical immunotherapy with diphencycloprenone when it all fails out: more than just a last resort
S. Mirhadi and A. Abdullah

Skin Cancer

P66  Radiological imaging in all stage III melanomas: current practice in the U.K.
G. Parkins, E. Brown and G. Gupta

P67  Preliminary data and the design of a new U.K.-wide trial (Rational MCC) comparing surgery vs. radiotherapy as the first definitive treatment for primary Merkel cell carcinoma
C. Harwood, C. Yap, J. Marsden, O. Cassell, C. Corner, P. Lawton, M. Moncrieff, H. Peach, C. Proby, R. Blundred, S. Rodwell and N. Steven

P68  Mitochondrial tolerance to single and repeat exposure to simulated sunlight in human skin cells
J. Kelly and J. Murphy

P69  Option grids in melanoma: improving shared decision making

P70  Neuroendocrine carcinoma in situ in association with Bowenoid epidermal dysplasia and squamous cell carcinoma
Y.W. Tsang, S. Taibjee, J. Carter and R. Carr

P71  Pathological prognostic features of small-diameter melanoma
H. Collett, B. Dawar, M. Darling, C. Moyes and G. Gupta

P72  Genetic and phenotypic heterogeneity in Ferguson–Smith disease: a case series
Z. Shukur, D. Goudie, N. Chung, S. Whittaker, A. Shaw and K. Lacy

P73  Diffuse large B-cell lymphoma in mycosis fungoides and Sézary syndrome: a case series
B. Chan, S. Morris, P. Fields, C. Stefanato, J. van der Walt, M. Moonim, D. Dasgupta and S. Whittaker

P74  Genetic and phenotypic heterogeneity in Ferguson–Smith disease: a case series
Z. Shukur, D. Goudie, N. Chung, S. Whittaker, A. Shaw and K. Lacy

P75  Incidence of lentigo maligna: a single health board experience, 1990–2010
M. Anderson, A. Evans and C. Fleming

P76  Examining the consistency of diagnosis, treatment and management of spitzoid lesions
N. Walmsley and K. Blasdale

P77  Mitochondrial tolerance to single and repeat exposure to simulated sunlight in human skin cells
J. Kelly and J. Murphy

P78  Skin cancer screening at the workplace in a large trading company
M. Haeberle

P79  Management of penile intraepithelial neoplasia: a retrospective observational study
H. Naasan, L. Long, S. Allstaff, P. Halliday and A. Affleck

P80  Skin cancer screening at the workplace in a large trading company
M. Haeberle

M. Anderson, A. Evans and C. Fleming

P82  Mitochondrial tolerance to single and repeat exposure to simulated sunlight in human skin cells
J. Kelly and J. Murphy

P83  Neuroendocrine carcinoma in situ in association with Bowenoid epidermal dysplasia and squamous cell carcinoma
Y.W. Tsang, S. Taibjee, J. Carter and R. Carr

P84  Diffuse large B-cell lymphoma in mycosis fungoides and Sézary syndrome: a case series
B. Chan, S. Morris, P. Fields, C. Stefanato, J. van der Walt, M. Moonim, D. Dasgupta and S. Whittaker
Therapy

P90 Improvement in the quality of life of patients with severe plaque psoriasis treated with systemic methotrexate in fixed doses of 10 mg or 25 mg orally once weekly: a prospective, randomized, double-blind, parallel-group study
C.V. Krishna and A.V.M. Rao

P91 Oral antibiotics for acne: are we adopting premium use?
H.J. Whitehouse, E. Fryatt, I. El-Mansori and A.M. Layton

P92 Secukinumab achieved ≥ 90% improvement in Psoriasis Area and Severity Index at weeks 16 and 52 in many patients with no or partial response at week 12
R. Williams, M. Tomlinson, Y. Armendariz and F. Allen

P93 A systematic review of oral anticholinergic medication in the treatment of hyperhidrosis
L. Crudas and D. Baker

P94 A prospective study to assess the efficacy of rituximab monotherapy in severe pemphigus vulgaris and relationship between T-regulatory-cell count in peripheral blood and disease severity
R. Bhattacharjee, D. De, S. Handa, R. Minz and B. Saikia

P95 Metformin use in hidradenitis suppurativa: the experience of a tertiary-referral hidradenitis suppurativa clinic
L. Jennings, R. Hughes, B. Moriarty and B. Kirby

P96 Systemic therapy for vulval erosive lichen planus (the ‘hELP’ Trial): a pilot randomized controlled trial
R. Simpson, T. Murphy and K. Thomas

P97 Efficacy and safety of ixekizumab in patients with psoriasis who failed initial etanercept treatment: a subanalysis from UNCOVER 2, a randomized, double-blind, multicentre, phase III clinical trial
C.E. Griffiths, R. Warren, D. Ilo, L. Kerr, T. Kent and L. Mallbris

P98 Extracorporeal photopheresis in Sézary syndrome: 8-year review of data from a cutaneous T-cell lymphoma registry

P99 Renal dysfunction in patients taking fumaric acid esters
S. Menzies, N. Ismail, A. Abdalla, P. Collins, B. Kirby, J. Holian and A. Lally

P100 Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients
E.N. Dhonncha, J. Clowry, M. Dunphy, C. Buckley, S. Field and L. Paul

P101 Long-term follow-up of imiquimod-treated lentigo maligna
M. Papanikolaou and C.M. Lawrence

P102 Bexarotene: a registry study of adverse effects in a population of patients with cutaneous T-cell lymphoma

P103 LIBERATE trial: sustained efficacy of apremilast in patients with moderate-to-severe psoriasis who continued on apremilast or switched from etanercept treatment
K. Reich, J. Soung, M. Gooderham, Z. Zhang, K. Nograles and M. Goodfield

P104 Practical implications of recent recommendations for monitoring lymphocyte counts in patients with psoriasis treated with fumaric acid esters
C.C. Foley, O.E. Molloy, S. Menzies, P. Collins, B. Moriarty, B. Kirby and A. Lally

P105 Comparative effectiveness of biological therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study

P106 Durable response rates with talimogene laherparepvec or granulocyte–macrophage colony-stimulating factor are associated with additional clinical benefits in patients with stage IIIB–IVM1a melanoma in the OPTiM trial
K. Harrington, R.H.I. Andtbacka, A. Melcher, R. Safaei, G. Downey, H.L. Kaufman and M. Middleton

P107 A novel treatment with topical timolol for drug-induced pyrogenic granulomas
B. Ganatra, S. Krishna, A. Tewari, A. Fogo and J. Natkunarajah


P109 Microretrodermal axillary curettage effectively reduces axillary hyperhidrosis
D. Vakili and D. Baker

P110 A review of the placebo rates of response in clinical trials of hidradenitis suppurativa
S. McCarthy, D. Sheehan, M. Murphy and F. Shanahan

P111 Dapsone effects the accuracy of glycated haemoglobin measurements and can have implications for monitoring glycaemic control or diagnosis of diabetes

P112 Secukinumab shows similar efficacy across baseline Dermatology Life Quality Index subgroups (≤ 10 or >10) in patients with moderate-to-severe psoriasis in two pivotal phase III studies (FIXTURE and ERASURE)
R. Williams, M. Tomlinson, Y. Armendariz and F. Allen

P113 Uptake of influenza and pneumococcal vaccinations in patients receiving methotrexate, ciclosporin, azathioprine and biologics
S.T. Ngu, E.V. Wray and G. Dawn

P114 Order and timing of applying emollients and topical corticosteroids in atopic eczema: a survey of U.K. patients and healthcare professionals

P115 DRESS (drug reaction with eosinophilia and systemic symptoms) vs. mini-DRESS: is there a spectrum of drug hypersensitivity?
S. Momen, D. Creamer and S. Walsh

P116 Isotretinoin blood monitoring in patients with acne: creating additional expense?
F. Cunningham and G. Wylie
AbbVie Ltd
Abbvie House, Vanwall Business Park, Maidenhead, Berkshire, SL6 4UB
TEL: +44 7786 020 334
WEBSITE: www.abbvie.com
EMAIL: hannah.watson@abbvie.com
CONTACT NAME/S: Hannah Watson
On January 1, 2013, AbbVie was founded as a global biopharmaceutical company with focus and capabilities to address some of the world’s greatest health challenges. AbbVie has the stability, resources, expertise, and passion to discover, develop and bring to market ground breaking science to solve the biggest health problems that face the world today and tomorrow.

Almirall Ltd
1 The Square, Stockley Park, Uxbridge UB11 1TD
TEL: 020 7160 2500

Athrodax/Waldmann
Hawthorn Business Park, Drybrook, Gloucester GL17 9HP
TEL: 01594 544 440
WEBSITE: www.athrodax.co.uk
EMAIL: sales@athrodax.co.uk
CONTACT NAME/S: Mrs Eve Hall
Athrodax and our partner Waldmann, will be displaying one of the latest full body phototherapy treatment cabins along with a selection of smaller robust phototherapy products. We will also be demonstrating innovative confocal laser scanning microscopy, skin mapping systems and digital dermoscopy in partnership with Mavig and Visiomed.

Athrodax/MAVIG/Visionemed
MAVIG GmbH VivaScope Systems
Stahlgruberring 5, 81829 Munich, Germany
TEL: +49(0)89-42096-268
WEBSITE: www.vivascope.eu
EMAIL: elisat@maquiv.com
CONTACT NAME/S: Birgit Elisat
Confocal laser scanning microscopy (CLSM) opens a “window into your skin”. CLSM enables dermatologists with real-time optical biopsy of skin – the living skin tissue can be analyzed without excising a pathological specimen. This innovative method is available in Europe for more than 10 years now. Visit www.vivascope.eu to learn more about VivaScope.

Visionemed AG
Osningsstrasse 25, Bielefeld 33605, Germany
TEL: +49 (0) 521 329 8560
WEBSITE: www.visionedag.de
EMAIL: post@visionedag.de
CONTACT NAME/S: Christian Feldbausch
MicroDERM® Skimmap - fully automated total body mapping system creates a standardised, total body map. The scanning process captures high resolution images of predefined skin areas from head to toe.

British Association of Dermatologists
The University of Manchester, Rutherford House (Unit 1 FF), Manchester Science Park, 40 Pencroft Way, Manchester, M15 6SZ
TEL: 0161 306 1896
FAX: 0161 306 1912
WEBSITE: www.bad.org.uk
CONTACT: Kathleen McElhone, BADBIR Manager
The BADBIR is a national register of patients receiving therapy for the treatment of moderate to severe psoriasis in the UK. Data is collected on patients treated with biologics or other systemic treatments (for control purposes). The primary aim of the register is to monitor the safety of biologic agents.

British Skin Foundation
Willan House, 4 Fitzroy Square, London W1T 5HQ
TEL: 0207 391 6341
WEBSITE: www.britishskinfoundation.org.uk
EMAIL: admin@britishskinfoundation.org.uk
The British Skin Foundation is the only UK based charity dedicated to funding research into all skin diseases.
Exhibitior Directory

Brymill Cryogenic Systems (UK) Ltd
26 Hayes View Drive, Walsall, WS6 7EX
TEL: 01256 841045
FAX: 01256 350330
WEBSITE: www.brymill.co.uk
EMAIL: sales@brymilluk.com
CONTACT NAME/S: Steve Williams
Brymill Cryogenic Systems has been the world leader in the design and manufacture of the Cryosurgical equipment for over 40 years. Brymill UK now supplies a wider range of quality products including Ethicon Sutures, Electrosurgery, HeadLights, Loupes, Dermatoscopes, Single Use Instruments, Woundcare Products and Smoke Evacuation systems. We shall also be lauching the Swift Microwave Generator.

Celgene
1 Longwalk Road, Stockley Park, Hillingdon UB11 1DB
TEL: +44 (0) 208 831 8300
WEBSITE: www.celgene.co.uk

Circle Nottingham
Nottingham NHS Treatment Centre, Queen’s Medical Centre Campus, Lister Road, Nottingham NG7 2FT
TEL: 0115 970 5800
WEBSITE: www.circlehealth.co.uk
EMAIL: kate.blake@circlenottingham.co.uk
andandy.addison@circlenottingham.co.uk
and catherine.jones@circlenottingham.co.uk
CONTACT NAME/S: Kate Blake, Andy Addison, Catherine Jones
You may have heard about Dermatology at the Nottingham NHS Treatment Centre. We are an employee co-owned partnership, with a social mission to make healthcare better for patients. If innovation, service development and opportunities weren’t the subject of the conversation, then you may not have heard the whole story.

Clinique Laboratories
Clinique Laboratories Limited, One Fitzroy, 6 Mortimer Street, London W1T 3JJ
TEL: BAD exhibitor - Charlotte Hough 0791 7555 470
Events Co-ordinator - Ana Chapman Clinique 0207 034 6923
WEBSITE: www.clinique.co.uk
EMAIL: BAD exhibitor - Charlotte Hough chough@clinique.co.uk
Events Co-ordinator - Ana Chapman anchapman@clinique.co.uk

Cynosure
Unit 2a, The Old Barn Offices, Long Lane, Cookham, Berkshire SL6 9EE
TEL: 01628 522 252
WEBSITE: www.cynosureuk.com
EMAIL: dneuhofer@cynosure.com
CONTACT NAME/S: Doug Neuhofer
Cynosure, Inc. leads the world in aesthetic laser technologies and research, creating innovative, safe, and efficacious procedures for the treatments patients want most, including hair removal, treatment of vascular and pigmented lesions, skin revitalization, tattoo removal, body contouring, and the reduction in the appearance of cellulite.

Dermal Laboratories Ltd
Tatmore Place, Gomsore, Hitchin, Herts SG4 7QR
TEL: 01462 45 88 66
WEBSITE: www.dermal.co.uk
EMAIL: info@dermal.co.uk
CONTACT NAME/S: Henrry Pyff
For over 50 years, Dermal have been developing highly eective, cosmetically acceptable and proven topical formulations for the management of dermatological conditions. Visit our stand to hear the latest news about our ongoing programme of clinical research, educational support for healthcare professionals and our newest development to assist with patient education.

Diagenics Ltd
South House 3, Bond Avenue, Bletchley, Milton Keynes MK1 1SW
TEL: 01908 376376
WEBSITE: www.diagenics.co.uk
EMAIL: info@diagenics.co.uk
CONTACT NAME/S: Jim Kambatta, Nick Lynch
Diagenics will be showing the truetest patch test system, which allows the rapid application of 35 pre-dispensed patches and patchprotect to ensure the security of application of the chambers. Information about our large range of skin prick test solutions will be available.

Eli Lilly & Co. Ltd
Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL
TEL: 01256 315 000
WEBSITE: www.lilly.co.uk

Espère Healthcare Ltd
Shefford House, 15 High St, Shefford, Bedfordshire SG17 5DD
TEL: 01462 346100
WEBSITE: www.esperehealth.co.uk
EMAIL: chris@esperehealth.co.uk
CONTACT: Chris Steeles, Jo Fletcher
Nine years on from its launch at the 2007 BAD in Birmingham, interest in DermaSilk Therapeutic Clothing has never been higher. We’ve over a dozen published papers in 5 disease areas and more to follow. Come and see just how much this technological advancement can offer you and your patients.

Fontus Health Ltd
60 Lichfield Street, Walsall WS4 2BX
TEL: 0121 661 4615
WEBSITE: www.aproderm.com
EMAIL: info@aproderm.com
CONTACT NAME/S: Daljit Birdi
Fontus Health is a UK based pharmaceutical company which has developed a range of creams to treat Eczema, Psoriasis and Dry Skin Conditions. The AproDerm range is free from sensitisers and has been dermatologically tested. Free samples are available for all Healthcare professionals to give out to their patients. Please visit www.aproderm.com.
Globe AMT

Globe Aesthetic & Medical Technologies

Unit D7, Sandown Industrial Park, Mill Road, Esher, Surrey, KT10 8BL
TEL: 01372 471100
WEBSITE: www.globeamt.com
EMAIL: sales@globeamt.com
CONTACT NAME/S: Yasmina Decaestecker, Neil Roberts

Within dermatology Globe AMT have assembled an advanced diagnostic portfolio with peer reviewed proven ability to improve diagnostic accuracy for the full range of skin lesions. The C-Cube digital dermoscopy system combined with Nevisense, to differentiate melanoma, ensures the highest percentage of accurate diagnoses compared to any other technology available.

HealthTemps

Luminous House, 300 South Row, Central Milton Keynes MK9 2FR
TEL: 01908 355800
WEBSITE: www.healthtemps.co.uk
EMAIL: info@healthtemps.co.uk
CONTACT NAME/S: Paul Starkey

HealthTemps is a specialist recruitment agency focussing on recruiting dermatologists into the NHS and private sectors. Offering unique opportunities, highly competitive salary packages and a fully supportive team available 24/7. Please come and speak with one of our specialist recruiters at stand D42 to find out how we can assist.

International Psoriasis Council

1034 S. Brentwood Blvd, Suite 600, St. Louis, MO 63117 USA
TEL: +1 972.861.0503
WEBSITE: www.psoriasiscouncil.org
EMAIL: info@psoriasiscouncil.org
CONTACT NAME/S: Christy Langan, CEO

The International Psoriasis Council (IPC) is a dermatology-led, voluntary, global non-profit organization dedicated to innovation across the full spectrum of psoriasis through research, education and patient care. IPC’s mission is to empower our network of global key opinion leaders to advance the knowledge of psoriasis, enhancing the care of patients worldwide. Visit us at www.psoriasiscouncil.org to learn more.

Intrapharm Laboratories

The Granary, The Courtyard Barns, Choke Lane, Cookham Dean, Maidenhead, Berkshire, SL6 6PT
TEL: 01628 771800
WEBSITE: www.intrapharmlabs.com
EMAIL: marisam@intrapharmlabs.com
CONTACT NAME/S: Marisa Broadbent

Intrapharm Laboratories is committed in providing well-known products with proven efficacy at the most affordable prices. We supply: Terra-Cortril Ointment - (3% oxytetraycline and 1% hydrocortisone) for infected eczema; does not contain preservatives. Provides a choice to physicians which has not been available to date. AquaMax Cream- This emollient is not only the most cost effective in comparison to other leading emollients but also has a higher moisturising lipid content providing longer lasting relief. Available in a 500g tub, 250g wash and 100g tube.

Janssen Pharmaceuticals

50-100 Holmers Farm Way, High Wycombe, Bucks HP12 4EG
TEL: +44 (0) 1494 567 831
WEBSITE: www.janssen.co.uk
EMAIL: pmruek@ITS.JNJ.com
CONTACT NAME/S: Peter Monk

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in immunology, oncology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world.

Johnson & Johnson Ltd

Foundation Park, Ruxborough Way, Maidenhead, SL6 3UG
TEL: 01628 822 222

At Johnson & Johnson Limited, we embrace research and science - bringing innovative ideas, products and services to support Healthcare Professionals and advance the health and well-being of people.

La Roche-Posay

La Roche-Posay, L’Oréal UK Ltd, 255 Hammersmith Road, London W6 8AZ
TEL: 0800 055 6822
WEBSITE: www.laroche-posay.co.uk
EMAIL: contact@laroche-posay.co.uk
CONTACT NAME/S: Elly Sandberg

Recommended by dermatologists worldwide, La Roche-Posay presents a comprehensive range of skincare solutions with proven efficacy and tolerance, suitable for all skin types, even sensitive. Our product range features carefully selected, highly concentrated active ingredients and unique La Roche-Posay Thermal Spring Water, renowned for its soothing and anti-oxidant properties.

LEO Pharma

Horizon, HoneyLane, Hurley, Berkshire SL6 6RJ
TEL: 01844 347333
WEBSITE: www.leo-pharma.co.uk
EMAIL: general.uk@leo-pharma.com
CONTACT NAME/S: Simon Rear

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions.

Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of R&D to delivering products and solutions to people with skin conditions.

LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

LEO® © LEO, DATE OF PREPARATION: March 2016, ALL LEO TRADEMARKS


MEDA Pharmaceuticals Ltd

Skyyway House, Parsonage Road, Bishop’s Stortford CM22 6PU
TEL: 0845 460 0000
WEBSITE: www.medapharma.co.uk
EMAIL: info@medapharma.co.uk

Meda is an international specialty pharma company with its own sales organisations in approximately 60 countries and operations expanding in growth markets. Meda is the 48th largest pharmaceutical company in the world. Our ever-expanding product portfolio covers a wide range of treatment areas with a focus in allergy and dermatology.

medac GmbH

Scion House, Stirling University Innovation Park, Stirling FK9 4NF
TEL: 01786 458059
WEBSITE: www.medacuk.co.uk
EMAIL: lauren.addison@medac-uk.co.uk
CONTACT NAME/S: Lauren Addison

medac GmbH is a privately owned German company founded in 1970. medac mainly promotes the development and marketing of therapeutics in the field of autoimmune diseases. Our Metoject® PEN...
is injectable methotrexate used in the treatment of severe psoriasis. Please come to stand E20 for more information.

**Mölnlycke Health Care**

Mölnlycke Health Care, 401 Grafton Gate, Milton Keynes, MK9 1AQ
TEL: 0800 7311 876
WEBSITE: www.molnlycke.co.uk
EMAIL: Kieran.gormley@molnlycke.com
CONTACT NAME/S: Kieran Gormley

Mölnlycke Health Care provides high-quality healthcare solutions for customers, healthcare professionals and patients worldwide. We develop and bring to market innovative wound care and surgical solutions throughout the entire continuum of care – from prevention to post-acute settings. Our solutions provide value for money, supported by clinical and health economic evidence.

**NAOS GROUP UK LTD (Bioderma)**

131-151 Great Titchfield Street, London W1W 5BB
TEL: 0203 700 3667
WEBSITE: www.bioderma-uk.com
CONTACT NAME/S: Lucie Moretti

At Bioderma, skin is our passion, our expertise, our model. It is by observing skin’s biology and analysing what it naturally does best, that we found the inspiration to create dermatological skin cares that restore its natural balance to strengthen it. The skin itself inspired BIODERMA to find biological solutions to preserve the health and beauty of our skin. In a lasting way.

**Novartis Pharmaceuticals UK Ltd**

200 Frimley Business Park, Frimley/Camberley, Surrey GU16 7SR
TEL: 01256 894000
WEBSITE: www.shirepharmaceuticals.co.uk
CONTACT NAME/S: Krista Pettitt

Shire has focus on rare diseases part of that being lysosomal storage disorders, within in that Fabry disease, which can present itself to dermatologists, we are present at BAD in order to raise awareness. Our first class technical knowledge has enabled us to develop products in conjunction with leading specialists to ensure superb performance. Our all new OPTICLAR Dermatoscope is packed with features and benefits significantly improving the quality of patient assessments.

**Opticlar - Albert Waeschle**

Unit 11 Balena Close, Creekmoor Industrial Estate, Poole, Dorset BH17 7DB
TEL: 01202 601177
WEBSITE: www.opticlar.co.uk
CONTACT NAME/S: John Hall

Albert Waeschle has been supplying the Dermoscopy profession for over thirty years. Our first class technical knowledge has enabled us to develop products in conjunction with leading specialists to ensure superb performance. Our all new OPTICLAR Dermatoscope is packed with features and benefits significantly improving the quality of patient assessments.

**Pern Consumer Products Ltd**

Sales, Marketing & Procurement, Newcastle Enterprise Centre, Unit 2-15, Quayside, i4 Albion Row, Newcastle upon Tyne NE6 1LL
TEL: 0800 599 9022
WEBSITE: www.dermacool.co.uk
EMAIL: phil.richardson@pern-consumer.co.uk
CONTACT NAME/S: Phil Richardson and Dee Malia-Richardson

The company will be highlighting their Menthol in aqeous cream brand Dermacool, especially the 5% strength. Delegates will also be able trial and take samples of the new SLS free formulation of Dermacool, plus other associated eczema & psoriasis skin treatments. For information contact Tel: 0800 599 9022 – www.dermacool.co.uk

**Premium Medical Protection Ltd**

68 Pure Offices, Plato Close, Tachbrook Park, Leamington Spa CV34 6WE
TEL: 0845 308 2350
WEBSITE: www.premiummedicalprotection.com
CONTACT NAME/S: Leslie Laird, Stacey Griffiths

Premium Medical Protection, provides bespoke Medical Professional Indemnity Insurance aiming to lower premiums whilst continuing to provide comprehensive cover up to £10m limit of liability and benefits such as consent to settle indefinite run off into retirement, subject to underwriting. Call 0845 308 2350 or www.premiummedicalprotection.com

**RB**

Welcroft House, Welcroft Road, Slough, SL1 4AQ
TEL: 0333 2005 345
WEBSITE: www.e45.co.uk
CONTACT NAME/S: Nishma Patel

E45 Cream for the relief of dry skin conditions.

**Sanofi Genzyme**

1 Onslow Street, Guildford, Surrey GU1 4YS
TEL: 01483 505515
WEBSITE: www.sanofi.co.uk
CONTACT NAME/S: Raj Rout, Medical Affairs, Immunology

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.

“Sanofi Genzyme and Regeneron are committed to providing resources to better understand and research atopic dermatitis”

**Schuco International**

Axis 4, Rhodes Way, Watford WD24 4YW
TEL: 01923 234 600
WEBSITE: www.schuco.co.uk
CONTACT NAME/S: Claire Callaway

**Shire**

Hampshire International Business Park, Chineham, Basingstoke Hampshire RG24 8EP
TEL: 01256 894000
WEBSITE: www.shabo.com
CONTACT NAME/S: Krista Pettitt

Shire has focus on rare diseases part of that being lysosomal storage disorders, within in that Fabry disease, which can present itself to dermatologists, we are present at BAD in order to raise awareness.

**Sobi**

1 Fordham House Court, Newmarket Road, Fordham, Cambridgeshire CB7 5LL
TEL: 01638 722386
WEBSITE: www.sobi.com
CONTACT NAME/S: Krista Pettitt

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primary focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, Australia, Asia Pacific and Russia.
STD Pharmaceuticals
Plough Lane, Hereford, HR4 0EL
TEL: 01432 373555
WEBSITE: www.stdpharm.co.uk
EMAIL: roliver@stdpharm.co.uk
CONTACT NAME/S: Richard Oliver
STD Pharmaceuticals are a small family run company that supply iontophoresis machines and other products for hyperhidrosis sufferers. Their iontophoresis machines are supplied to most UK hospitals and patients and their range of ‘sweatstop’ products are supplied via their website www.sweatstop.co.uk STD also supply disposable underarm pads called ‘esteem’ http://www.esteemclothingprotectors.co.uk

Stiefel, a GSK Company
GlaxoSmithKline, Iron Bridge Road, Stockley Park West, Uxbridge
UB11 1BT
WEBSITE: www.stiefel.com

Thornton & Ross Limited
Linthwaite, Huddersfield, HD7 5QH
TEL: 01484 842217
WEBSITE: www.trderma.co.uk
EMAIL: elliotadams@thorntonross.com
CONTACT NAME/S: Elliot Adams
Thornton & Ross Dermatology offer the following skin care solutions; Zeroderma emollients - similar in formulation to leading brands and offering cost savings of up to 37%. Cetraben emollients - offering unique formulations to enable effective eczema management. Flexitol – medically proven treatments for dry, cracked feet associated with diabetic anhydrosis.

Unite Medical Ltd
12 Business Centre, The Pinnacle, Midsummer Boulevard, Milton Keynes MK9 1BP
WEBSITE: www.unitemedical.org
EMAIL: info@unitemedical.org
CONTACT NAME/S: Andrew Hollingsworth, Nathan Romeo
National medical recruitment and locum agency, providing bespoke services to the NHS and private sector.

Vichy Dermablend
3rd Floor ACD, L’Oreal UKI, 255 Hammersmith Road, London W6 8AZ
TEL: 020 8762 4000
WEBSITE: www.dermablend.co.uk
EMAIL: emma.lewis@loreal.com
CONTACT NAME/S: Emma Lewis/Carlos Otalora
Vichy Dermablend is a high coverage, long hold foundation range with a natural looking finish. Designed for all skin types (including sensitive skin) and skin concerns including acne, scars, tattoos, vitiligo, rosacea and uneven skin tone, Dermablend continues to give women confidence. Recommended by Dermatologists, Used by Make Up Artists.

Wisepress Medical Bookshop
25 High Path, Merton Abbey, London SW19 2JL
TEL: +44 20 8715 1812
WEBSITE: www.wisepress.com
EMAIL: marketing@wisepress.com
CONTACT NAME/S: Hannah Leach
Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks
General Information

DELEGATE BAGS
The Conference & Events Department is aiming to limit the impact the Annual Meeting has upon the environment.

Conferences and exhibitions provide a huge amount of waste and this year we aim to continue to implement measures to improve this.

Following feedback from previous meetings delegates will be provided with a generic delegate bag (as illustrated). This bag is made from recycled plastic bottles and has the BAD Logo on the side.

We have made a decision not to include a sponsor, date or annual meeting destination. This will enable you to reuse the bag for other annual meetings as well as other BAD meetings. We hope this will become your BAD 'Bag for Life'.

If you have a bag from a previous annual meetings please bring it with you.

EVALUATION FORM
This year’s evaluation form will be on-line and all attendees will be sent a link after the meeting.

Thank you in advance for taking the time to complete it, as it is an invaluable tool for us in organising future meetings.

CES MEETINGS CALENDAR

August 2016
Survival Guide for New Trainees
Venue: Willan House, London
Date: 4th August

September 2016
13th Congress of the European Society of Contact Dermatitis
Venue: Manchester Central
Date: 14th - 17th September 2016
Essential Cutaneous Infections
Venue: Willan House, London
Date: 19th September

October 2016
Clinical Dermatology Update Meeting
Meeting for Staff and Associate Specialist Doctors
Venue: Crew Hall
Date: 5th - 7th October

6th World Congress of Teledermatology
Venue: Royal College of Physicians, London
Date: 14th - 15th October

November 2016
Dermdoc
Venue: Willan House, London
Date: 7th November

StR Training Event
Venue: Willan House, London
Date: 10th – 11th November

BCDG Annual Meeting
Venue: Willan House, London
Date: 12th November

British Association of Paediatric Dermatology Annual Meeting
Venue: Sheffield
Date: 18th -19th November

The Annual UK Dermatology Course for Consultants
Venue: Hilton Paddington Hotel, London
Date: 25th - 26th November

For Further Details on any of these meetings please contact:
Conference & Event Services,
4 Fitzroy Square, London W1T 5HQ
Email: conference@bad.org.uk
Tel: + (0)20 7391 6358

Join our facebook Group
Follow us on Twitter
Library of Birmingham (Presidents Private dinner)

OPUS (BSDS dinner)
RECIPE FOR 20 YEARS OF BRITISH SKIN FOUNDATION SUCCESS

TAKE 10,000 SUPPORTERS, RAISING OVER £15 MILLION.

ADD 600 RESEARCHERS COMPLETING 330 PROJECTS AT 25 UNIVERSITIES AND MEDICAL SCHOOLS THROUGHOUT THE UK.

MATURE FOR 20 YEARS AND WITNESS THE COUNTLESS LIVES CHANGED THROUGH TWO DECADES OF BRITISH SKIN FOUNDATION RESEARCH FUNDING.

For further information and to find out how you can help, please visit:
www.britishskinfoundation.org.uk  call 0207 391 6341
www.facebook.com/leadingthefightagainstskindisease
@BSFCharity
On Thursday 13th October 2016 the British Skin Foundation will be holding a unique 20th anniversary event to take place at the Royal College of Physicians, London.

‘Skin Deep – 20 years of Research’ is a professional 1 day CPD accredited conference, highlighting the work supported by the BSF.

There will be a selection of key note and oral research presentations and an e-poster display.

**Session 1**
Infection and inflammatory mechanisms

**Session 2**
Population genetics and epidemiology

**Session 3**
Cancer treatments and mechanisms

Although there are a limited 150 places, registration is free.

Please email sarah@britishskinfoundation.org.uk, for further details and a registration form.

---

**British Skin Foundation**
4 Fitzroy Square, London, W1T 5HQ
www.britishskinfoundation.org.uk
Telephone: 020 7391 6341
Registered Charity Number 313865
Stiefel is a global leader in skin science and innovation

At Stiefel, we are serious about skin. We understand the daily impact skin conditions can have on people’s lives and the challenges of treatment. We are inspired by the difference healthy skin can make.

We focus on individual skin needs to deliver an integrated portfolio of prescription treatments and skincare products.

Not content with results that bring only partial or temporary improvement, we are committed to finding effective, long-lasting solutions. We listen, using our expertise and an open, collaborative approach to address the real challenges faced by physicians and skincare experts.

By being part of GSK, we can reach further, drawing on global resources and world-renowned R&D in our mission to discover and develop innovative, science-led solutions that make a meaningful difference and raise expectations of skin health.

With our commitment, drive and willingness to innovate, Stiefel is dedicated to helping more people discover and enjoy healthy skin.

www.stiefel.com
©2015 Stiefel Laboratories, Inc. All Rights Reserved.
UK/STIEFEL/0005/16, Date of preparation – May 2016